https://trial.medpath.com/news/ac80e6eb09ab20e6/diamyd-medical-new-publication-highlights-safety-and 2010-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0ed95b7e8372a5dd/new-publication-highlights-safety-and-potential-benefits-of-redosing 2010-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9809643390d06438/results-from-diamyd-r-antigen-specific-immunotherapy-trial-in-lada 2010-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b32c3f3451b7491d/diamyd-medical-receives-u-s-fda-fast-track-designation-for-diamyd-r 2010-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e16415673d14bc1/diamyd-medical-receives-positive-feedback-from-fda-on-potential 2010-01-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e5a8b93ed59b9d89/orchard-therapeutics-receives-innovation-passport-for-gene-therapy-otl-201-targeting-rare-sanfilippo-syndrome 2026-04-30T13:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/4fff209b8e5a0e0b/evotec-secures-9-9-million-in-gates-foundation-grants-to-advance-next-generation-tuberculosis-therapies 2026-04-30T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/66d7edd70d066985/parexel-acquires-ai-powered-pharmacovigilance-platform-vitrana-to-enhance-patient-safety-technology 2026-04-30T05:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/e42b287f1f31cb00/novel-radiotracer-shows-promise-for-non-invasive-endometriosis-diagnosis-in-phase-2-trial 2026-04-30T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/8401bf70240b8b79/astrazeneca-exercises-option-for-pinetree-s-first-in-class-egfr-degrader-in-500m-deal 2026-04-30T05:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/11c59f88a2ce9c20/acrobiosystems-and-seromyx-systems-partner-to-advance-anti-cd20-monoclonal-antibody-research-through-comprehensive-functional-profiling 2026-04-30T05:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/17c1c42b2321ab35/vivacta-bio-secures-over-50-million-in-series-a-funding-to-advance-in-vivo-car-t-therapy-gt801 2026-04-30T05:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/afdbfd4cee62464e/novo-nordisk-s-denecimig-achieves-99-reduction-in-bleeding-episodes-for-hemophilia-a-patients-in-phase-3-trial 2026-04-30T01:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/52885a9f65df19a3/acrux-advances-female-testosterone-therapy-to-phase-iii-for-hsdd-treatment 2026-04-30T01:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/6c429628ba494fd7/medtronic-s-mosaic-neo-mitral-valve-receives-fda-approval-launches-with-rapid-clinical-adoption 2026-04-30T01:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/b6d74e6d5a2dae4d/circular-genomics-and-vitazi-ai-partner-to-develop-ai-powered-multimodal-alzheimer-s-detection-platform 2026-04-29T21:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/f60345aaa9b88e0b/lts-lohmann-expands-cdmo-services-into-ophthalmic-drug-delivery-at-new-jersey-facility 2026-04-29T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/a55593676ef10105/xtl-biopharmaceuticals-acquires-psyga-bio-to-create-leading-psychedelic-therapeutics-platform-following-trump-executive-order 2026-04-29T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/471215f1839360a7/strand-therapeutics-names-kunal-bhatia-as-cfo-to-scale-programmable-mrna-platform 2026-04-29T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/12f8b5eef726fab5/bd-launches-first-all-in-one-central-line-insertion-system-to-enhance-patient-safety 2026-04-29T17:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/13a6215ab52dbef6/ptc-therapeutics-reports-positive-24-month-data-for-votoplam-in-huntington-s-disease-extension-study 2026-04-29T13:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/0c294af30df2cb06/hutchmed-s-sovleplenib-receives-priority-review-and-breakthrough-designation-in-china-for-rare-blood-disorder 2026-04-29T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/d7863f1612a56231/thermo-fisher-scientific-opens-flagship-u-s-bioprocess-design-center-to-accelerate-biologics-development 2026-04-29T05:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/8a42b843b3509a94/health-canada-approves-first-generic-semaglutide-making-canada-first-g7-nation-to-authorize-glp-1-generic 2026-04-29T01:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/f39a1964c9b2cbea/ucla-develops-see-cite-technology-to-enhance-precision-in-drug-discovery-and-protein-binding-analysis 2026-04-29T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/a8e816b235fabf86/anova-enterprises-reaches-500-urology-research-sites-in-digital-clinical-trial-network 2026-04-28T21:09:25+00:00 hourly 0.9 https://trial.medpath.com/news/8d670691dde25f2f/c-ray-therapeutics-secures-fda-approval-for-copper-64-drug-master-file-advancing-next-generation-pet-diagnostics 2026-04-28T21:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/36a49d822815d4c6/ventripoint-s-ai-powered-cardiac-imaging-system-vms-4-0-submitted-for-expedited-regulatory-approval-in-china 2026-04-28T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/4bc640233d510e21/pfizer-secures-patent-extension-for-vyndamax-through-2031-in-generic-settlement-deals 2026-04-28T21:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/1973852792e88400/fda-launches-real-time-clinical-trial-monitoring-pilot-with-astrazeneca-and-amgen-cancer-studies 2026-04-28T21:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/1a8b31ff1fadf06f/artelo-biosciences-partners-with-ai-company-sciencemachine-to-accelerate-fabp5-inhibitor-development 2026-04-28T17:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/812c24871dce4a39/vensica-medical-receives-fda-ind-clearance-for-phase-2-trial-of-needle-free-botulinum-toxin-delivery-system-for-overactive-bladder 2026-04-28T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/ae085c2f9751eb7a/fda-grants-breakthrough-device-designation-to-laguna-diagnostics-blood-based-test-for-psychiatric-disorder-differentiation 2026-04-28T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/d1edb8494f0708e8/coultreon-biopharma-secures-125m-series-a-to-advance-novel-sik3-inhibitor-for-autoimmune-diseases 2026-04-28T17:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/b9a0e5e3ab4985a6/abbott-receives-fda-clearance-for-ultreon-3-0-ai-powered-coronary-imaging-platform 2026-04-28T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/502aadf0b2407d97/arcera-life-sciences-and-fosun-pharma-form-strategic-partnership-to-bridge-chinese-innovation-with-global-markets 2026-04-28T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/a0b5a963af5277bc/verified-clinical-trials-and-chubb-form-strategic-alliance-to-enhance-clinical-trial-safety-and-data-integrity 2026-04-28T17:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/1d3c8814a30292ea/histoindex-expands-ai-driven-mash-diagnostic-network-with-new-texas-and-california-partnerships 2026-04-28T13:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/ef3b0d77a6111a22/carb-x-awards-2-6-million-to-adjane-for-gonorrhea-vaccine-development-using-nomv-platform 2026-04-28T13:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/06cc75e23bb33d60/merck-kgaa-partners-with-remepy-to-pioneer-hybrid-drugs-combining-pharmaceuticals-with-digital-therapeutics 2026-04-28T13:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/622be92c8e00909a/mark-cuban-s-cost-plus-drugs-partners-with-humana-to-transform-employer-prescription-benefits 2026-04-28T05:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/ba4139c0fa1fdae8/medicinova-s-ibudilast-shows-promise-for-brain-metastasis-treatment-in-new-cnio-research 2026-04-28T05:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/0315b88675d8c9ea/umoja-biopharma-unveils-industry-s-first-dual-targeted-bcma-x-gprc5d-in-vivo-car-t-therapy-for-multiple-myeloma 2026-04-28T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/4645e0b1017a9235/sana-biotechnology-to-present-preclinical-data-on-novel-in-vivo-car-t-therapy-sg293-at-asgct-2026 2026-04-28T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/a25377ec0711c626/pooled-cord-blood-stem-cell-product-achieves-96-survival-rate-in-blood-cancer-transplant-trial 2026-04-28T01:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/f145ebf3f64e23e3/sunnybrook-health-sciences-centre-receives-41-million-donation-to-transform-clinical-trial-infrastructure-in-canada 2026-04-28T01:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/b1d3b832edf4950f/dapsone-combination-therapy-reverses-alzheimer-s-biomarkers-in-chronic-lyme-disease-patient 2026-04-27T21:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/ef90e07140e96ed0/msk-researchers-uncover-pancreatic-cancer-cell-cooperation-mechanism-and-demonstrate-adc-efficacy-in-rare-pediatric-sarcoma 2026-04-27T21:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/6c082849c06a3503/canadian-drug-pipeline-reaches-10501-medicines-with-cancer-treatments-dominating-development 2026-04-27T21:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/30eb4359ad940d78/ligand-pharmaceuticals-acquires-xoma-royalty-for-739-million-expanding-portfolio-to-over-200-drug-assets 2026-04-27T17:11:45+00:00 hourly 0.9 https://trial.medpath.com/news/e30a54a47bbbd890/blood-filtering-treatment-shows-promise-for-severe-early-preeclampsia-in-small-clinical-trial 2026-04-27T17:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/e214f6e676c6d078/stealth-biotherapeutics-completes-phase-1-trial-of-bevemipretide-eye-drops-for-dry-amd 2026-04-27T17:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/18137c97120e8806/uk-biotech-financing-rebounds-18-in-q1-2026-as-venture-capital-activity-surges 2026-04-27T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/a062f3a5ab051e37/apollomics-advances-c-met-inhibitor-vebreltinib-toward-fda-submission-following-strategic-turnaround 2026-04-27T17:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/4b65fb1d7dba6d20/pci-pharma-services-announces-1-billion-investment-in-us-manufacturing-expansion 2026-04-27T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/63ac0ac49d2930cc/symptom-based-opioid-dosing-reduces-hospital-stay-for-newborns-with-withdrawal-syndrome 2026-04-27T17:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/fcbc38e57af5fe19/sibel-health-secures-3-5-million-arpa-h-contract-to-develop-first-in-class-wearable-edema-monitor 2026-04-27T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/ab010b673d2a572a/duvelisib-shows-promising-results-in-relapsed-refractory-peripheral-t-cell-lymphoma-phase-2-trial 2026-04-27T17:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/151dfeb88841c589/xcovery-partners-with-eversana-to-expand-commercial-launch-of-alk-positive-nsclc-drug-ensacove 2026-04-27T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/f2778f3547bc98bc/fda-approves-caplyta-for-schizophrenia-relapse-prevention-based-on-phase-iii-data 2026-04-27T17:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/8def16f7a835b69c/cms-secures-exclusive-rights-to-market-advanced-intravenous-iron-therapies-in-china-through-15-year-partnership-with-pharmacosmos 2026-04-27T13:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/d3f36d1e6ab03a5e/repurposed-drugs-show-promise-for-treating-aggressive-infant-leukemia-in-preclinical-studies 2026-04-27T13:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/8d84a1136e366a65/bd-and-suttons-creek-form-strategic-alliance-to-streamline-combination-product-development-for-pharma-and-biotech 2026-04-27T13:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/8e4dd66601011c60/eli-lilly-acquires-ajax-therapeutics-for-2-3-billion-to-advance-novel-jak2-inhibitor-for-blood-cancers 2026-04-27T13:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/40683ff7d2012a72/intellia-s-crispr-gene-therapy-achieves-87-reduction-in-hereditary-angioedema-attacks-in-phase-3-trial 2026-04-27T13:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/4c2f7ef488c72960/motif-neurotech-receives-fda-approval-for-first-clinical-trial-of-wireless-brain-implant-for-treatment-resistant-depression 2026-04-27T13:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/b07e5d60f1af8565/cellenkos-receives-fda-clearance-for-phase-2-trial-of-ck0801-allogeneic-treg-therapy-in-aplastic-anemia 2026-04-27T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/e002b99ea605779f/paradigm-biopharmaceuticals-secures-14m-to-advance-phase-3-osteoarthritis-trial-through-interim-analysis 2026-04-27T06:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/7b8effa000406a35/jw-pharmaceutical-completes-phase-3-dosing-for-gout-drug-epaminurad-in-multi-country-asian-trial 2026-04-27T06:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/f6f8d3bd5e423acc/boan-biotech-advances-phase-ii-trial-for-novel-anti-cd25-antibody-combination-in-nsclc 2026-04-27T06:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/d4857335c72d5f88/sun-pharma-to-acquire-organon-for-11-75-billion-in-major-women-s-health-and-biosimilars-expansion 2026-04-27T06:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/3ed55f5a924a76d7/immunitybio-secures-revised-dunkirk-manufacturing-deal-with-stricter-terms-and-40m-investment-commitment 2026-04-26T21:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/65777a34196b3e5c/novo-nordisk-continues-real-world-study-of-refixia-in-japanese-hemophilia-b-patients 2026-04-26T21:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/e2f156c8083b93f5/bioengineered-chewing-gum-shows-promise-against-cancer-linked-oral-microbes-in-head-and-neck-cancer-patients 2026-04-26T14:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/2c1336d0c63cab3b/brii-bio-reports-durable-immunological-control-in-hepatitis-b-combination-therapy-analysis 2026-04-26T14:33:23+00:00 hourly 0.9 https://trial.medpath.com/news/25ab76d367b328e5/utah-biotech-startup-claims-breakthrough-in-lab-grown-human-sperm-technology 2026-04-26T09:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/2f9b3310b9fc756d/zydus-lifesciences-receives-phase-iii-approval-for-novel-anti-malarial-drug-zintrodiazine 2026-04-25T21:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/1cd5b9ebafe910b8/endoscopic-procedure-shows-promise-in-preventing-weight-regain-after-glp-1-drug-discontinuation 2026-04-25T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/7f1caef10068cf64/berlin-heals-reports-positive-first-in-human-results-for-less-invasive-heart-failure-device-implantation 2026-04-25T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/af5efe0b646b13d6/fda-fast-tracks-review-of-three-psychedelic-drugs-for-depression-and-mental-health-treatment 2026-04-25T13:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/ed18b0e4db0ac212/johnson-johnson-expands-medtech-portfolio-with-atraverse-medical-acquisition-and-viz-ai-partnership 2026-04-25T05:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/76139aaef4f3e14c/stony-brook-cancer-center-enrolls-patients-in-phase-3-breast-cancer-vaccine-trial-targeting-her2-positive-disease 2026-04-25T05:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/aa236d26bb518159/actg-launches-phase-2-trial-comparing-pramipexole-to-escitalopram-for-depression-and-cognitive-disorders-in-hiv-patients 2026-04-25T05:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/3a5ae283f135a592/russia-develops-gene-therapy-targeting-rage-receptor-to-combat-cellular-aging 2026-04-25T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/976609a01dce4717/large-international-trial-shows-no-difference-between-fluid-types-for-pediatric-septic-shock-treatment 2026-04-25T01:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/571ab14eb886e911/frankfurt-court-upholds-arbitral-award-securing-besremi-access-for-polycythemia-vera-patients 2026-04-24T21:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/4cc72579251c2302/eight-year-study-confirms-long-term-safety-and-efficacy-of-tenofovir-alafenamide-for-chronic-hepatitis-b-in-chinese-patients 2026-04-24T21:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/58e929d42b70f545/entelo-bio-emerges-from-stealth-with-4m-to-advance-ai-driven-movement-disorder-therapeutics 2026-04-24T21:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/7f36e8919a908856/hansoh-biotech-presents-novel-bispecific-antibody-and-adc-research-at-aacr-2026 2026-04-24T21:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/71d9377b01574824/plopii-files-patent-for-paraxanthine-based-headache-pill-to-replace-caffeine-in-otc-analgesics 2026-04-24T21:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/b571ef8b8e1c23b8/axsome-s-symbravo-shows-long-term-benefits-in-migraine-disability-and-quality-of-life 2026-04-24T21:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/2f505ca4e2ad1394/arizona-launches-first-clinical-trial-using-whole-psilocybin-mushrooms-for-first-responder-ptsd-treatment 2026-04-24T21:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/c39ad258f11b6037/ucb-opens-eur200-million-gene-therapy-manufacturing-facility-in-belgium 2026-04-24T17:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/1ee144a4e799fc78/jaguar-health-reports-promising-results-for-crofelemer-in-rare-pediatric-intestinal-failure-conditions 2026-04-24T17:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/1bdaf2a6c79da9db/bristol-myers-squibb-and-pfizer-launch-eliquis-on-mark-cuban-s-cost-plus-drugs-platform 2026-04-24T13:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/f0e4c5e6e1b2fb2b/ai-platform-identifies-traditional-chinese-medicine-compounds-for-alzheimer-s-disease-treatment 2026-04-24T13:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/b201cc55d7f1c73f/biomede-trial-reveals-biomarker-driven-strategy-for-pediatric-brain-cancer-despite-missing-primary-endpoint 2026-04-24T13:07:40+00:00 hourly 0.9 https://trial.medpath.com/news/997b563cbbca6676/novartis-receives-positive-chmp-opinion-for-itvisma-gene-therapy-for-spinal-muscular-atrophy 2026-04-24T13:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/c36ba32e4e94626f/ai-clinical-trial-market-projected-to-reach-54-7-billion-by-2030-as-industry-embraces-predictive-analytics 2026-04-24T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/0fc332530b4c1346/clinuvel-receives-ema-scientific-advice-for-pivotal-phase-iii-vitiligo-study-using-totality-of-evidence-approach 2026-04-24T05:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/1dab30d2d87fae00/nephrology-experts-outline-four-critical-strategies-to-improve-global-kidney-disease-trial-success-rates 2026-04-24T03:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/4e84e8f14d58f14b/f2g-s-olorofim-shows-promise-in-high-risk-hematology-patients-with-invasive-aspergillosis 2026-04-24T01:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/b2b2b66c33c77c34/freeze-dried-platelet-product-shows-promise-for-traumatic-brain-injury-treatment 2026-04-24T01:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/5ae40023d5dcd1e9/fda-rejects-abbvie-s-trenibote-wrinkle-treatment-over-manufacturing-issues 2026-04-24T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/1eed4ae71e479f6d/hytn-innovations-spins-out-bpc-157-peptide-drug-development-business-for-ligament-disorders 2026-04-24T01:04:39+00:00 hourly 0.9 https://trial.medpath.com/news/8f18ac531b239c61/fda-issues-complete-response-letter-for-abbvie-s-novel-botulinum-toxin-trenibote-over-manufacturing-concerns 2026-04-24T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/de3221b115a8fba8/uw-medicine-launches-clinical-trial-of-cnp-103-to-preserve-insulin-production-in-type-1-diabetes 2026-04-24T01:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/6e29b2c4411c2b7a/regeneron-strikes-final-drug-pricing-deal-with-white-house-offers-free-gene-therapy-for-rare-hearing-loss 2026-04-23T21:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/b1cf8cf6d229adea/theialife-appoints-thomas-ruggia-as-ceo-to-lead-phase-3-development-of-first-in-class-oral-myopia-therapy 2026-04-23T17:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/4d9f89cff8fa6cc8/cumberland-pharmaceuticals-sells-commercial-portfolio-to-apotex-for-100m-refocuses-on-orphan-drug-pipeline 2026-04-23T17:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/9eac230ab39ea4f3/ge-healthcare-doses-first-patient-in-phase-2-3-trial-of-manganese-based-mri-contrast-agent 2026-04-23T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/aea2c22fa4d0c854/trump-administration-reclassifies-cannabis-to-schedule-iii-opening-new-research-pathways 2026-04-23T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/5c2d501b859dc078/repertoire-immune-medicines-initiates-first-in-human-trial-of-novel-tcr-bispecific-therapy-for-advanced-solid-tumors 2026-04-23T17:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/ea179354f4bc5f55/paxlovid-speeds-recovery-but-fails-to-reduce-hospitalizations-in-vaccinated-covid-19-patients 2026-04-23T05:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/ebdb017cf8034150/federal-judge-allows-eli-lilly-lawsuit-against-compounded-tirzepatide-seller-to-proceed 2026-04-23T05:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/4f20d5270a36b3c3/vietnam-announces-plans-to-join-international-mrna-cancer-vaccine-clinical-trials-starting-2026 2026-04-23T05:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/dc00daefceee633b/prestige-biopharma-files-patent-for-novel-subcutaneous-antibody-delivery-platform-idc224 2026-04-23T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/4ad969c66405acbc/certara-divests-regulatory-and-medical-writing-business-to-veristat-for-135-million-to-focus-on-ai-driven-drug-development 2026-04-23T01:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/ff25cf9e9028ac81/xeltis-receives-eu-ce-mark-for-bioabsorbable-hemodialysis-graft-following-successful-120-patient-trial 2026-04-23T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/92a3bae89d55eadf/six-year-old-girl-regains-vision-through-groundbreaking-nhs-gene-therapy-for-leber-s-congenital-amaurosis 2026-04-22T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/9bbacfcd1ef2b28a/10x-science-raises-4-8m-to-automate-protein-characterization-with-ai-platform 2026-04-22T21:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/d1d52cdc3d6a1c96/evonik-invests-eur80-million-to-expand-biopharma-manufacturing-capacity-in-slovakia 2026-04-22T21:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/7db17e261b7c233f/experimental-drug-dh20931-shows-promise-against-triple-negative-breast-cancer-through-novel-lipid-targeting-mechanism 2026-04-22T21:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/fc3f5bc915d25414/first-in-class-anti-netrin-1-antibody-shows-promise-in-pancreatic-cancer-phase-1b-trial 2026-04-22T17:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/f5a92627daac83f1/rafael-holdings-secures-exclusive-mit-license-for-cyclodextrin-therapy-targeting-apoe4-positive-alzheimer-s-patients 2026-04-22T17:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/c531f81e32e8f814/made-scientific-partners-with-regenicin-to-advance-novaderm-autologous-skin-substitute-toward-fda-approval 2026-04-22T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/e21edadeb7774dbd/mindera-health-receives-new-york-state-approval-for-mind-px-psoriasis-precision-medicine-test 2026-04-22T17:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/97194de9926fa2b3/fda-grants-orphan-drug-designation-to-pegrizeprument-for-heart-transplant-rejection-prevention 2026-04-22T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/4af338d53087b6c6/amneal-pharmaceuticals-acquires-kashiv-biosciences-for-750-million-to-create-global-biosimilar-leader 2026-04-22T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/23cd229db803a1c3/united-laboratories-advances-dual-pipeline-with-fda-approval-for-tul321-and-china-approval-for-dupilumab-biosimilar 2026-04-22T17:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/7c8483b9027bd5d3/redhill-s-opaganib-shows-promise-in-neuroblastoma-and-triple-negative-breast-cancer-preclinical-studies 2026-04-22T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/f75d3740ccf05fa6/thryv-therapeutics-initiates-phase-2-3-trial-for-long-qt-syndrome-treatment-receives-fda-fast-track-designation 2026-04-22T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/357744edf9b3b4c9/aavantgarde-presents-interim-luce-1-trial-data-for-usher-syndrome-1b-gene-therapy-at-arvo-2026 2026-04-22T13:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/3df8fbbf4cfd45d5/major-pharma-companies-compete-for-8-billion-inhibrx-cancer-drug-that-could-enhance-keytruda 2026-04-22T13:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/88876701ed9c266a/puretech-s-lyt-200-shows-promising-results-in-phase-1b-trial-for-relapsed-refractory-blood-cancers 2026-04-22T13:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/f063ed76a4163373/calluna-pharma-completes-enrollment-in-phase-2-aurora-study-of-cal101-for-idiopathic-pulmonary-fibrosis 2026-04-22T09:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/065baf8a91c74d9b/dayspring-pharma-s-cg2001-foam-shows-50-efficacy-improvement-in-phase-ii-androgenetic-alopecia-trial 2026-04-22T09:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/5e67ebdf4fdb7473/innovent-advances-first-in-class-ibi363-to-pivotal-trials-for-immunotherapy-resistant-lung-cancer 2026-04-22T05:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/d4f90e29aa8edd8b/novi-health-s-hybrid-care-model-achieves-clinical-trial-level-weight-loss-in-real-world-glp-1-treatment 2026-04-22T05:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/1f073c7b9f11230d/rgenta-therapeutics-to-present-phase-1-clinical-data-on-rna-targeting-cancer-drug-rgt-61159-at-asco-2026 2026-04-22T01:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/1b9e1e4327bec052/sidra-medicine-becomes-first-hospital-in-qatar-to-offer-crispr-gene-therapy-for-sickle-cell-disease-and-thalassemia 2026-04-22T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/a0e3a4d623daba66/singapore-led-studies-demonstrate-breakthrough-treatments-for-challenging-women-s-cancers 2026-04-21T21:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/6d3e7676c93a9310/injectable-nivolumab-shows-promise-for-precancerous-oral-lesions-in-phase-i-trial 2026-04-21T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/b4623318dc356420/enspryng-achieves-68-reduction-in-mogad-relapses-in-pivotal-phase-iii-trial 2026-04-21T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/17b50ac25a4ae369/incyte-to-present-positive-phase-3-frontmind-data-for-tafasitamab-in-first-line-dlbcl-at-asco-2026 2026-04-21T21:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/8b07e4dd8025c1e9/fda-clears-expanded-indications-for-sinefix-orthopedic-implant-across-multiple-soft-tissue-repair-applications 2026-04-21T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/6411d8721361b6e1/cerracap-ventures-invests-in-nephronomics-to-advance-ai-driven-kidney-disease-drug-discovery 2026-04-21T21:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/423ff56297b6b1e2/aulos-bioscience-reports-promising-phase-1-2-results-for-ai-designed-melanoma-therapy-at-asco-2026 2026-04-21T17:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/78c21ca6b6bc0b6a/crown-bioscience-and-turbine-partner-to-integrate-ai-driven-drug-discovery-with-organoid-validation-platform 2026-04-21T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/38b6d3c57e5cdbae/cemdisiran-achieves-breakthrough-results-in-phase-3-myasthenia-gravis-trial-positioning-for-first-sirna-approval 2026-04-21T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/7dcbd29e24669887/gen1e-and-rubicon-research-form-strategic-partnership-to-advance-ai-driven-precision-medicine-platform 2026-04-21T17:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/ecfb6b0576be8d6f/minaris-achieves-100-manufacturing-success-rate-for-chimeric-therapeutics-cdh17-car-t-cancer-program 2026-04-21T17:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/1016aa1551594aba/bpgbio-appoints-former-oxford-innovation-chief-chas-bountra-as-cso-to-advance-mitochondrial-therapeutics-pipeline 2026-04-21T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/85c92c584de654ba/bioaegis-partners-with-prenosis-to-develop-ai-driven-precision-medicine-for-ards-treatment 2026-04-21T17:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/0b474aa799f5bde2/star-therapeutics-receives-fda-rare-pediatric-disease-and-breakthrough-therapy-designations-for-vga039-in-von-willebrand-disease 2026-04-21T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/6c070c21fd5e59c3/paradigm-health-launches-spire-platform-to-transform-post-approval-clinical-evidence-generation 2026-04-21T17:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/3a97903b717a5272/tortugas-neuroscience-emerges-from-stealth-with-106m-to-advance-cns-drug-pipeline-licensed-from-eisai-and-hansoh 2026-04-21T17:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/dac1e6bf2490ce47/inbrain-completes-first-in-human-trial-of-graphene-brain-interface-with-no-safety-issues 2026-04-21T13:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/8525dd692368aaf1/flagship-pioneering-launches-serif-biomedicines-with-50m-to-pioneer-modified-dna-therapeutics 2026-04-21T13:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/b4164ee2a68d0d32/addex-gabab-pam-candidate-shows-promising-anti-cough-activity-in-non-human-primate-studies 2026-04-21T09:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/43dab11369d676b7/leinco-technologies-and-cellcarta-form-strategic-partnership-to-advance-proteomics-in-immuno-oncology-drug-development 2026-04-21T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/38bcb57ccd8a561b/conavi-medical-receives-fda-clearance-for-first-hybrid-ivus-oct-intravascular-imaging-system 2026-04-21T01:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/f48b373472d2dc72/rusan-pharma-secures-pmda-japan-gmp-approval-for-api-and-injectable-manufacturing-facilities 2026-04-21T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/03ffee86bc816992/inhibrx-to-present-clinical-update-on-ozekibart-in-late-line-colorectal-cancer 2026-04-21T01:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/ee18bc6050ce71df/flatiron-health-publishes-first-peer-reviewed-validation-framework-for-ai-extracted-real-world-oncology-data 2026-04-20T22:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/59eac6194e455106/phase-i-lung-cancer-trials-consolidate-at-major-u-s-medical-centers-raising-access-concerns 2026-04-20T22:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/80dd8c285ff54cdc/accord-biopharma-s-ustekinumab-biosimilar-imuldosa-gains-preferred-status-on-cigna-healthcare-formularies 2026-04-20T18:43:54+00:00 hourly 0.9 https://trial.medpath.com/news/33a45c9103ff36f8/huxley-health-launches-aerasyn-biotech-division-secures-15m-financing-for-psychedelic-therapeutics-platform 2026-04-20T18:41:10+00:00 hourly 0.9 https://trial.medpath.com/news/b5ef6362d36f8b42/abogen-s-mrna-encoded-t-cell-engager-abo2203-shows-promise-in-b-cell-lymphoma-with-superior-safety-profile 2026-04-20T18:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/38cd7dc97ed5c9e8/viewsml-raises-4-9m-to-commercialize-ai-powered-virtual-biomarker-staining-technology 2026-04-20T18:36:31+00:00 hourly 0.9 https://trial.medpath.com/news/68e3d0231c2b768f/health-canada-approves-jamp-pharma-s-golimumab-biosimilar-prupgolyv-for-autoimmune-diseases 2026-04-20T18:35:41+00:00 hourly 0.9 https://trial.medpath.com/news/7e7bdfccc836c9b6/orion-pharma-s-odm-212-receives-fda-orphan-drug-designation-for-mesothelioma-treatment 2026-04-20T18:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/e65a6913f2976154/boehringer-ingelheim-launches-ps150m-ai-accelerator-in-london-to-advance-drug-discovery 2026-04-20T18:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/9ed867fc0ba50c3f/sapience-therapeutics-reports-47-response-rate-for-first-in-class-b-catenin-antagonist-st316-in-second-line-colorectal-cancer 2026-04-20T18:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/35a08ac06521eeec/st-david-s-south-austin-medical-center-enrolls-first-patient-globally-in-phase-iii-car-t-cell-trial-for-aggressive-large-b-cell-lymphoma 2026-04-20T18:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/ce81571402a06eaf/biogen-acquires-global-rights-to-felzartamab-with-850-million-deal-for-greater-china-assets 2026-04-20T13:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/2eafeff67a376e49/toronto-ai-startup-biossil-raises-70m-to-resurrect-failed-drug-candidates-using-large-language-models 2026-04-20T13:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/9faebc57ef3aaf28/chong-kun-dang-enrolls-first-u-s-patient-in-global-phase-1-2a-trial-of-adc-cancer-drug-ckd-703 2026-04-20T13:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/e433943a21546699/novo-nordisk-s-etavopivat-achieves-breakthrough-results-in-phase-3-sickle-cell-disease-trial 2026-04-20T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/335cd061ec602ada/askbio-advances-commercial-scale-manufacturing-for-parkinson-s-gene-therapy-in-phase-ii-trial 2026-04-20T13:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/4adb44b0fc830238/bracco-imaging-and-nyu-langone-health-form-strategic-alliance-to-advance-medical-imaging-innovation 2026-04-20T13:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/8b6379270116d0b6/cellbxhealth-partners-with-royal-marsden-to-enhance-lung-cancer-treatment-through-ctc-dna-analysis 2026-04-20T13:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/0d0f9af73b425cca/cumberland-pharmaceuticals-receives-fda-approval-for-expanded-caldolor-indication-in-postoperative-pain-management 2026-04-20T09:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/8d2db67186d04281/hk-inno-n-partners-with-nextgen-to-advance-ipf-drug-nxc680-into-phase-1-clinical-trials 2026-04-20T05:03:52+00:00 hourly 0.9 https://trial.medpath.com/news/f23bbc650caf3046/nexalis-therapeutics-initiates-phase-2-trial-for-irx-211-in-breakthrough-cancer-pain 2026-04-20T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/6980d52849149078/hiv-treatment-reverses-accelerated-biological-aging-by-nearly-four-years-swiss-study-reveals 2026-04-20T01:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/c8d59c09491d8172/revolution-medicines-kras-drug-shows-strong-results-at-aacr-2026 2026-04-20T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/0ccedc7c2cc151a8/xuanzhu-biopharma-s-diluoake-demonstrates-superior-efficacy-over-crizotinib-in-phase-iii-alk-positive-nsclc-trial 2026-04-19T17:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/f3d95bdb8fefe0fa/samsung-bioepis-confirms-consistent-efficacy-of-osteoporosis-biosimilar-obodence-across-diverse-patient-populations 2026-04-19T09:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/49364f47ddea6b2e/scientists-win-3-million-prize-for-breakthrough-research-leading-to-first-crispr-sickle-cell-therapy 2026-04-19T05:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/81691972200aa269/fda-issues-first-warning-letter-for-inappropriate-ai-use-in-drug-manufacturing 2026-04-19T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/98541f68b16ab19f/biolamina-secures-eur20m-eib-loan-to-scale-laminin-technology-for-cell-therapy-manufacturing 2026-04-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/f957a5fd24b5b752/philadelphia-scientists-win-3-million-breakthrough-prize-for-first-fda-approved-gene-therapy-for-inherited-blindness 2026-04-19T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/5c8dbf7978c6981f/evotec-se-s-drug-discovery-partnership-model-gains-traction-as-pharma-outsourcing-accelerates 2026-04-18T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/7eefcb73584b359b/extended-immunotherapy-shows-safety-profile-in-rare-alveolar-soft-part-sarcoma-beyond-standard-two-year-treatment 2026-04-18T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/b03532f28d8e1733/blood-pressure-drug-candesartan-cilexetil-shows-promise-against-mrsa-infections-in-laboratory-study 2026-04-18T17:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/ecaf56011a155fd3/sanofi-s-nuvaxovid-covid-19-vaccine-demonstrates-superior-tolerability-profile-compared-to-mrna-vaccine-in-head-to-head-study 2026-04-18T13:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/c23e13b5796b5fbe/model-medicines-secures-first-us-patent-for-ai-discovered-broad-spectrum-antiviral-mdl-001 2026-04-18T09:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/77f05071ad4245f2/rznomics-rna-therapy-shows-23-complete-response-rate-in-liver-cancer-trial 2026-04-18T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/8bf40dc3b5920db7/asco-expands-tapur-study-with-first-antibody-drug-conjugate-and-braf-mek-inhibitor-combination 2026-04-18T01:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/e81913fa812e4c09/biolojic-design-s-ai-designed-bd200-shows-superior-anti-tumor-activity-in-preclinical-studies-targeting-dual-cancer-antigens 2026-04-17T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/73dfc6902a4bcca1/onconano-s-ph-sensitive-nanotechnology-platform-shows-promise-for-antigen-independent-cancer-drug-delivery 2026-04-17T21:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/1c45893ea8ec326e/salubris-biotherapeutics-reports-promising-phase-1-2-data-for-5t4-targeted-adc-jk06-in-multiple-solid-tumors 2026-04-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/8937a69d4666a5a8/ucb-acquires-neurona-therapeutics-for-1-15-billion-to-advance-regenerative-cell-therapy-for-drug-resistant-epilepsy 2026-04-17T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/8b9a9a110b654c7e/byondis-unveils-novel-adc-platforms-to-combat-cancer-drug-resistance-at-aacr-2026 2026-04-17T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/b46a44f82cb1ce7a/luxturna-gene-therapy-shows-functional-benefits-despite-structural-decline-in-real-world-study 2026-04-17T17:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/2d55850e9abb8324/medicus-pharma-seeks-orphan-drug-designation-for-skinject-in-rare-gorlin-syndrome 2026-04-17T17:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/9ee11b80fbe903e9/marengo-therapeutics-reports-confirmed-complete-responses-in-phase-2-trial-of-invikafusp-alfa-plus-trodelvy-for-metastatic-breast-cancer 2026-04-17T17:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/6ffaef91fc486127/penetrium-bioscience-claims-breakthrough-in-tumor-microenvironment-targeting-to-overcome-cancer-drug-resistance 2026-04-17T17:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/38f2ec6533373f7c/biomarker-led-trials-emerge-as-key-strategy-for-precision-psychiatry-development 2026-04-17T13:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/dfda3182b583839a/donor-derived-cell-therapy-enables-immunosuppression-withdrawal-in-liver-transplant-patients 2026-04-17T13:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/63dad5b00cb44497/bioxodes-strengthens-clinical-advisory-board-and-advances-biox-101-pivotal-trial-for-intracerebral-hemorrhage 2026-04-17T13:03:34+00:00 hourly 0.9 https://trial.medpath.com/news/5672e802e9589eb3/biomed-x-and-servier-launch-ai-driven-bispecific-antibody-engineering-team-in-france 2026-04-17T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/23726d32322aafcc/alembic-pharmaceuticals-receives-fda-approval-for-generic-methotrexate-injection 2026-04-16T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/9a53b5551974a5eb/fda-encourages-testosterone-therapy-manufacturers-to-pursue-expanded-indication-for-low-libido 2026-04-16T21:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/00631dfc8be449b6/fda-approves-first-generic-version-of-farxiga-for-type-2-diabetes-and-cardiovascular-disease 2026-04-16T21:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/2807bc15352204fe/city-of-hope-launches-multi-cancer-study-of-quest-diagnostics-haystack-mrd-test-across-14-sites 2026-04-16T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/67bf5cf7b50d3ea1/meiragtx-reacquires-gene-therapy-botaretigene-sparoparvovec-from-johnson-johnson-for-x-linked-retinitis-pigmentosa-treatment 2026-04-16T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/c78ec1b26e25464a/icer-calls-for-enhanced-transparency-in-fda-s-accelerated-approval-pathway 2026-04-16T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/5b49306a0be2a698/latvian-study-reveals-77-long-term-cure-rate-for-multidrug-resistant-tuberculosis-far-exceeding-who-estimates 2026-04-16T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/2de80c8696dd2521/federal-circuit-reinstates-177-million-patent-verdict-for-teva-s-migraine-drug-ajovy-against-eli-lilly 2026-04-16T17:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/74bb1a29d76b122a/elephas-biosciences-and-mithrl-combine-real-time-tumor-profiling-with-ai-to-advance-immunotherapy-response-prediction 2026-04-16T17:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/752113cdbf5df363/zyus-life-sciences-completes-phase-2a-utopia-1-trial-for-novel-non-opioid-cancer-pain-treatment 2026-04-16T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/44bd6cfd80248cc3/achieve-life-sciences-secures-354-million-funding-for-cytisinicline-development-as-fda-review-continues 2026-04-16T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/22467475b2a56ec7/roche-acquires-saga-diagnostics-for-595m-to-enhance-foundation-medicine-s-cancer-monitoring-portfolio 2026-04-16T17:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/1ca969f04bd8e688/mytomorrows-and-rare-disease-research-partner-to-streamline-clinical-trial-access-for-rare-disease-patients 2026-04-16T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/1a91d3039a26e260/panthera-biopartners-expands-european-clinical-trial-network-with-hungarian-acquisition 2026-04-16T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/5b647f07e960d689/alethio-therapeutics-unveils-atx-011-first-in-class-mutation-agnostic-antibody-for-essential-thrombocythemia-treatment 2026-04-16T13:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/0b6e38d67f8f69a1/medera-receives-fda-fast-track-designation-for-gene-therapy-targeting-duchenne-muscular-dystrophy-associated-cardiomyopathy 2026-04-16T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/319d9afe8366750d/freya-biosciences-reports-positive-phase-1-results-for-fb301-in-ivf-related-embryo-implantation-failure 2026-04-16T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/16c5ab65f892548d/trabectedin-irinotecan-combination-shows-promise-against-ews-fli1-fusion-in-ewing-sarcoma-phase-1-2-trial 2026-04-16T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/d1880b2dc28c046b/scirent-appoints-cardiac-electrophysiology-expert-prof-dr-wilhelm-haverkamp-as-chief-medical-officer 2026-04-16T13:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/bb603ed85fbd23b3/aurobindo-pharma-s-theranym-biologics-expands-msd-partnership-with-175-million-mammalian-manufacturing-facility 2026-04-16T13:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/e6ede50519c45ec6/viatris-recalls-xanax-xr-3mg-tablets-nationwide-due-to-dissolution-failure 2026-04-16T09:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/90fd625cb3adc16d/storm-therapeutics-secures-56m-series-c-to-advance-first-in-class-mettl3-inhibitor-stc-15-in-phase-ii-sarcoma-trial 2026-04-16T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/7d3ec4bc02884bfc/mabwell-achieves-global-first-with-nmpa-acceptance-of-novel-lilrb4-cd3-bispecific-antibody-for-blood-cancers 2026-04-16T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/6fd4a3f02aa452fb/comprehensive-review-confirms-alzheimer-s-amyloid-targeting-antibodies-show-minimal-clinical-benefit-despite-plaque-clearance 2026-04-16T09:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/209bce951e7fa640/diakonos-oncology-s-experimental-immunotherapy-shows-90-survival-improvement-in-glioblastoma-phase-i-trial 2026-04-16T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/2b5ba499414f01b5/china-s-nmpa-accepts-mabwell-s-supplemental-application-for-denosumab-biosimilar-maiweijian-to-prevent-skeletal-events-in-cancer-patients 2026-04-16T05:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/97416cc918de0065/elion-therapeutics-initiates-phase-2-trial-of-turletricin-for-invasive-mould-infections 2026-04-16T01:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/5b5fefaea7c5c643/clearnote-health-s-avantect-pancreatic-cancer-test-achieves-82-6-sensitivity-in-early-detection 2026-04-16T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/7dbb70217cd683bb/alivecor-receives-ce-mark-for-portable-12-lead-ecg-system-with-ai-powered-cardiac-detection 2026-04-16T01:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/3e4c3ecc82bbadc3/medtronic-s-in-pact-av-drug-coated-balloon-shows-sustained-real-world-efficacy-in-dialysis-patients 2026-04-16T01:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/47c7eaed5be78b86/replimune-lays-off-200-employees-following-second-fda-rejection-of-melanoma-treatment-rp1 2026-04-15T23:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/094f3f968700761b/pds-biotech-s-immunocytokine-adc-shows-78-response-rate-in-colorectal-cancer-trial 2026-04-15T23:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/6b5acd186c37c491/cms-proposes-to-eliminate-alternative-payment-pathway-for-breakthrough-medical-devices 2026-04-15T23:22:11+00:00 hourly 0.9 https://trial.medpath.com/news/9d78755596c0de41/litmys-and-konovo-form-strategic-partnership-to-transform-drug-development-intelligence 2026-04-15T17:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/67fbf32a2553bac0/dutch-drup-trial-demonstrates-significant-potential-for-off-label-cancer-drug-use-in-advanced-patients 2026-04-15T17:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/71ee577ce3e0cb01/oncohost-unveils-proteomic-aging-biomarkers-for-immunotherapy-response-prediction-at-aacr-2026 2026-04-15T17:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/1ae0bc755031b418/filana-therapeutics-simufilam-shows-dose-dependent-seizure-reduction-in-tuberous-sclerosis-complex-mouse-model 2026-04-15T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/9d82f21e03d0b9c5/nucleai-and-sirona-dx-form-strategic-partnership-to-advance-spatial-proteomics-in-drug-development 2026-04-15T17:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/f411d6c26eeba651/penn-state-launches-phase-ii-trial-of-dfmo-for-pediatric-bone-cancers-following-fda-approval-in-neuroblastoma 2026-04-15T17:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/5be1fdc47d1f0474/biognosys-partners-with-michael-j-fox-foundation-to-develop-critical-lrrk2-biomarker-assays-for-parkinson-s-disease 2026-04-15T17:04:20+00:00 hourly 0.9 https://trial.medpath.com/news/b3ea18085238def2/beeline-medicines-emerges-with-300m-series-a-and-bristol-myers-immune-disease-pipeline 2026-04-15T17:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/b815697758a40406/labcorp-launches-first-fda-cleared-rapid-fentanyl-test-made-in-us-delivers-results-in-10-minutes 2026-04-15T13:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/12f9190543d778ee/arbutus-receives-fda-fast-track-designation-for-hepatitis-b-rnai-therapeutic-imdusiran 2026-04-15T13:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/2864221800834e8d/c-mo-medical-solutions-receives-ce-mark-for-ai-powered-cough-monitoring-system 2026-04-15T13:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/5566594dda20f3a6/yellowbird-diagnostics-initiates-first-in-human-trial-of-novel-inflammation-imaging-agent-neucavis 2026-04-15T13:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/e847121b66563439/shionogi-invests-in-restore-vision-s-gene-therapy-for-retinal-blindness-through-first-cvc-deal 2026-04-15T13:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/1a6768be809ea1a3/two-phase-2-trials-fail-to-demonstrate-cognitive-benefits-in-schizophrenia-despite-different-mechanisms 2026-04-15T13:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/cc09621e60e5d16c/isofol-medical-expands-phase-ib-ii-trial-for-arfolitixorin-in-colorectal-cancer-following-german-regulatory-approval 2026-04-15T13:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/bd330570b0c93477/synusight-s-sst001-a-synuclein-pet-tracer-receives-nmpa-approval-for-phase-i-clinical-trial-in-china 2026-04-15T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/d2be6372e152ccc1/fda-issues-draft-guidance-on-next-generation-sequencing-for-gene-therapy-safety-assessment 2026-04-15T01:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/cf73933f7b1759cc/vasa-therapeutics-partners-with-lilly-tunelab-to-accelerate-ai-driven-camkii-inhibitor-development 2026-04-14T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/a8949d49a51828b5/toby-s-urine-based-multi-cancer-detection-test-receives-fda-breakthrough-device-designation 2026-04-14T21:12:37+00:00 hourly 0.9 https://trial.medpath.com/news/6052b0ee6f4a07b3/impact-biotech-reports-promising-early-results-for-padeliporfin-vtp-in-pancreatic-cancer-eyes-strategic-partnerships 2026-04-14T21:11:32+00:00 hourly 0.9 https://trial.medpath.com/news/7ab58cd3183d8f5b/lantern-pharma-launches-withzeta-ai-world-s-first-multi-agentic-ai-co-scientist-for-rare-cancer-drug-discovery 2026-04-14T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/f8eae053f8b99a94/obsidian-and-galera-therapeutics-announce-350-million-merger-to-advance-next-generation-til-cell-therapy 2026-04-14T21:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/8c281b4064473678/rivus-pharmaceuticals-initiates-phase-ii-amplify-trial-for-hu6-in-mash-treatment 2026-04-14T21:10:30+00:00 hourly 0.9 https://trial.medpath.com/news/8299f65a120ae537/eli-lilly-acquires-crossbridge-bio-for-up-to-300-million-to-advance-dual-payload-adc-technology 2026-04-14T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/9f4cb36ccb261a71/hinge-bio-initiates-first-in-human-trial-of-hb2198-novel-dual-target-b-cell-depleting-therapy-for-autoimmune-diseases 2026-04-14T21:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/ae7cc33b872b5144/phrontline-biopharma-s-tj106-shows-promise-against-her2-low-and-adc-resistant-tumors-in-preclinical-studies 2026-04-14T21:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/e78b9b5a38d18094/vectorbuilder-launches-mutefree-aav-technology-to-solve-itr-instability-in-gene-therapy-manufacturing 2026-04-14T21:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/caaba6d189eda0e0/debiopharm-reports-first-clinical-data-from-mythic-trial-combining-wee1-and-pkmyt1-inhibitors-at-aacr-2026 2026-04-14T21:03:41+00:00 hourly 0.9 https://trial.medpath.com/news/7d713f539d0a6ac9/medline-recalls-angiographic-syringes-after-fda-warning-over-life-threatening-disconnection-risk 2026-04-14T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/aa406f5a4a58aa1a/single-cell-analysis-reveals-immune-dynamics-of-moderna-covid-19-vaccine-in-pregnant-women 2026-04-14T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/c1eba9207510030d/birmingham-receives-ps10m-to-build-advanced-biomanufacturing-facility-for-cell-and-gene-therapies 2026-04-14T13:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/76e4d951228133e7/fda-guidance-and-regulatory-uncertainty-create-challenges-for-us-biosimilar-market-development 2026-04-14T13:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/96924eb3ffb92434/adcendo-secures-75-million-series-c-to-advance-first-in-class-adc-pipeline-for-high-unmet-need-cancers 2026-04-14T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/3313b8df7f9d01ca/artcline-completes-patient-recruitment-for-septic-shock-immune-cell-therapy-trial 2026-04-14T13:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/5a586c9f381a6f24/asgard-therapeutics-appoints-veteran-oncologist-as-cmo-to-advance-novel-cancer-immunotherapy-at-108 2026-04-14T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/7e81299a2a29ee46/panntherapi-advances-phase-2a-trial-for-rare-epilepsy-drug-pti5803-targeting-pannexin-1-channel 2026-04-14T09:05:51+00:00 hourly 0.9 https://trial.medpath.com/news/e6d3a3c7e0a9cdfa/ailux-appoints-former-astrazeneca-executive-maria-belvisi-as-chief-scientific-officer-to-lead-drug-development-strategy 2026-04-14T09:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/7efea373be4e1bf0/fda-grants-fast-track-designation-to-daretabart-for-high-risk-neuroblastoma-treatment 2026-04-14T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/4a8837559769670a/protaryx-medical-receives-fda-510-k-clearance-for-transseptal-puncture-device 2026-04-14T05:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/2ea1d93eed3f3b4a/eclipse-life-sciences-completes-enrollment-in-phase-2-trial-of-ec-104-for-diabetic-macular-edema 2026-04-14T01:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/61e76ad0882e1ef2/fda-issues-2200-notices-to-companies-and-researchers-over-unpublished-clinical-trial-results 2026-04-14T01:10:46+00:00 hourly 0.9 https://trial.medpath.com/news/e88fea18ce705c06/scripps-health-receives-12-7-million-grant-to-develop-scaffold-free-stem-cell-therapy-for-knee-cartilage-repair 2026-04-14T01:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/06c673a9e2a7c55f/veld-pharmaceuticals-partners-with-chiesi-to-launch-rare-disease-access-program-across-africa 2026-04-14T01:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/19ee195ac1227fa7/maryland-sets-first-drug-price-cap-on-diabetes-medication-jardiance-at-204-per-month 2026-04-13T21:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/610fb796773f42a2/bioora-partners-with-cincinnati-children-s-to-advance-next-generation-car-t-therapy-for-pediatric-leukemia 2026-04-13T21:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/1a12f2d6d078b7f1/real-world-study-shows-trastuzumab-deruxtecan-improves-five-year-survival-in-her2-positive-metastatic-colorectal-cancer 2026-04-13T21:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/d1694a233e849d62/abbvie-secures-745m-licensing-deal-with-haisco-for-pain-pipeline-assets 2026-04-13T21:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/d20bcd47a9509629/airway-therapeutics-strengthens-board-with-cormedix-ceo-joe-todisco-as-zelpultide-alfa-advances 2026-04-13T21:06:59+00:00 hourly 0.9 https://trial.medpath.com/news/7b38ac35d738d7fa/nih-sponsored-trial-shows-stent-placement-significantly-reduces-post-thrombotic-syndrome-severity 2026-04-13T17:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/6490a6b550cb653c/frontier-medicines-appoints-former-seagen-ceo-david-epstein-to-board-as-company-advances-covalent-precision-medicine-pipeline 2026-04-13T17:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/59cba901acda053f/akebia-therapeutics-initiates-phase-1-trial-of-akb-9090-for-cardiac-surgery-associated-acute-kidney-injury 2026-04-13T17:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/725a7feb2062b069/norwegian-oslo-patient-achieves-hiv-remission-following-stem-cell-transplant-with-rare-genetic-mutation 2026-04-13T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/68261471c8dfb0f8/prosomnus-receives-fda-clearance-for-first-theragnostic-sleep-apnea-device-combining-oral-therapy-with-continuous-monitoring 2026-04-13T13:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/774993e934cb2f6c/haisco-partners-with-abbvie-in-745-million-pain-therapy-licensing-deal 2026-04-13T13:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/00778715d9aeedab/os-therapies-strengthens-strategic-advisory-board-with-industry-luminaries-craig-eagle-and-robert-langer 2026-04-13T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/1221a4c32136783a/spyre-therapeutics-spy001-demonstrates-promising-efficacy-in-phase-2-ulcerative-colitis-trial 2026-04-13T13:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/c9c9b916517776cf/roche-receives-ce-mark-for-elecsys-nfl-blood-test-to-monitor-multiple-sclerosis-neuroinflammation 2026-04-13T13:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/626e33d3b72c0765/synox-therapeutics-reports-positive-phase-3-results-for-emactuzumab-in-tenosynovial-giant-cell-tumor 2026-04-13T09:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/12608dbc68d50a66/st-pharm-secures-first-japanese-patent-for-mrna-lnp-platform-technology-stp1244 2026-04-13T05:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/c728275f7cc93b4d/yuhan-s-yh35995-receives-fda-orphan-drug-designation-for-gaucher-disease-treatment 2026-04-13T05:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/7062cdd1a864ba02/zeto-receives-fda-clearance-for-new-wave-eeg-system-to-address-outpatient-neurodiagnostic-delays 2026-04-13T05:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/921e34162a36e3dc/telix-and-regeneron-form-2-1-billion-strategic-partnership-to-develop-next-generation-radiopharmaceuticals 2026-04-13T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/09efc4268245a022/miracell-receives-fda-510-k-clearance-for-smart-m-cell-stem-cell-extraction-system 2026-04-12T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/a9d899c2a15aefc2/breakthrough-nanodisc-platform-reveals-hidden-viral-vulnerabilities-for-hiv-and-ebola-vaccine-development 2026-04-12T17:04:08+00:00 hourly 0.9 https://trial.medpath.com/news/093d1a718f306973/alligator-bioscience-partners-with-unicancer-to-explore-phase-3-trial-for-pancreatic-cancer-drug-mitazalimab 2026-04-11T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/df5be72d18c680f8/hanx-biopharmaceuticals-presents-four-innovative-cancer-therapies-at-2026-aacr-annual-meeting 2026-04-11T09:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/d90f160dac2d58a5/korea-university-and-mfc-partner-to-develop-muscle-loss-therapeutics-for-space-missions 2026-04-11T09:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/77ea9c813db6ef1b/hemab-therapeutics-files-for-nasdaq-ipo-to-advance-bleeding-disorder-therapies 2026-04-11T01:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/8a0055925375a7f1/amneal-pharmaceuticals-launches-generic-bimatoprost-for-glaucoma-treatment 2026-04-10T21:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/f752c75c670997b7/three-novel-therapies-target-frail-hnscc-patients-unable-to-tolerate-standard-treatment 2026-04-10T21:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/f5848893433bebf6/vivatides-therapeutics-raises-54-million-series-a-to-advance-extrahepatic-rna-therapeutics-platform 2026-04-10T21:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/7b86f1fa470198fd/amneal-pharmaceuticals-leverages-glp-1-manufacturing-partnership-with-pfizer-to-expand-beyond-traditional-generics 2026-04-10T21:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/40fbac272f3ead8f/canada-invests-50-million-to-build-critical-medicines-production-centre-in-alberta 2026-04-10T17:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/e248052a1f30a41e/ai-analysis-of-reddit-posts-reveals-unreported-glp-1-drug-side-effects-including-reproductive-and-temperature-symptoms 2026-04-10T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/33c9ef5ad2339a75/iaso-bio-partners-with-instituto-butantan-to-bring-car-t-cell-therapy-to-brazil-s-public-health-system 2026-04-10T17:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/288b80093ad19e87/ema-issues-urgent-safety-alert-for-cenobamate-following-severe-liver-injury-reports 2026-04-10T17:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/430db6119e2fb2ca/severe-enterocolitis-emerges-as-rare-but-fatal-complication-of-bcma-car-t-therapy 2026-04-10T17:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/0b97b564ed2cd1db/kura-oncology-to-present-updated-darlifarnib-combination-data-for-renal-cell-carcinoma-at-ikcs-europe-2026 2026-04-10T13:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/1c56ca872341fb43/ailsynbio-and-dong-e-e-jiao-partner-to-advance-ai-driven-traditional-chinese-medicine-research 2026-04-10T13:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/5af0ad19777c1e2d/cdc-acting-director-delays-publication-of-study-showing-covid-19-vaccine-effectiveness 2026-04-10T13:05:15+00:00 hourly 0.9 https://trial.medpath.com/news/03242bc7018b0454/amgen-s-bispecific-antibody-tarlatamab-receives-china-approval-for-small-cell-lung-cancer 2026-04-10T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/88c1e955bb89884a/france-becomes-first-nation-to-approve-iv-ketamine-for-acute-suicidal-crisis 2026-04-10T13:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/484f8786f4f9e08c/ascendis-pharma-completes-direct-listing-transition-on-nasdaq-exchanges-all-adss-for-ordinary-shares 2026-04-10T09:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/dcbf45d5f577ab3a/arkbio-initiates-first-in-human-trial-of-novel-long-acting-influenza-drug-ak0406-in-australia 2026-04-10T05:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/45fa93117cd6e352/allrock-bio-initiates-phase-iia-trial-of-first-in-class-oral-rock-inhibitor-for-pulmonary-hypertension 2026-04-10T01:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/fa5f49283f2d7306/nextbiomedical-secures-exclusive-japan-distribution-deal-for-nexsphere-f-embolization-device 2026-04-10T01:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/37ae42efb5cd1898/nmg-secures-297-million-financing-package-to-advance-graphite-mining-operations-for-battery-materials 2026-04-10T01:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/270745fc15f243b1/oxford-biotherapeutics-partners-with-bristol-myers-squibb-to-develop-next-generation-t-cell-engagers-for-solid-tumors 2026-04-09T21:08:22+00:00 hourly 0.9 https://trial.medpath.com/news/4dcd01a2a05ced80/university-of-waterloo-study-shows-natural-compounds-enhance-alzheimer-s-antibody-therapies 2026-04-09T21:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/4fcdac2602bc48d1/galenusrx-and-clutch-health-form-strategic-partnership-to-enhance-complex-patient-care-through-precision-medicine-and-behavioral-incentives 2026-04-09T21:06:14+00:00 hourly 0.9 https://trial.medpath.com/news/c0d90c4b08054931/kelun-biotech-achieves-hkex-milestone-with-b-marker-removal-advances-global-adc-pipeline 2026-04-09T21:06:09+00:00 hourly 0.9 https://trial.medpath.com/news/ca3f9c747b895675/deepcyte-secures-1-5m-seed-funding-to-advance-ai-powered-single-cell-toxicology-platform 2026-04-09T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/a6c998bc7896da40/covar-receives-darpa-contract-to-develop-ai-system-for-medical-decision-making-enhancement 2026-04-09T21:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/9175676d946deb26/click-therapeutics-secures-50m-series-d-to-commercialize-breakthrough-digital-therapeutic-for-schizophrenia 2026-04-09T17:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/c6d2dcd09eb26fa8/byondis-appoints-christoph-korpus-as-ceo-to-lead-adc-technology-platform-development 2026-04-09T17:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/8e0e1a873c050d25/rani-therapeutics-strengthens-leadership-team-with-key-strategic-appointments-to-advance-oral-biologics-platform 2026-04-09T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/a2de1d7a372e1496/glenmark-receives-fda-approval-for-generic-progesterone-vaginal-inserts-in-59-2-million-market 2026-04-09T17:12:01+00:00 hourly 0.9 https://trial.medpath.com/news/c68991598ee2f0c6/sanofi-acquires-market-authorization-for-nuvaxovid-covid-19-vaccine-in-canada 2026-04-09T17:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/e2e075f2011588a9/oncoc4-initiates-first-in-class-anti-siglec-10-antibody-trial-for-alzheimer-s-disease-treatment 2026-04-09T17:07:10+00:00 hourly 0.9 https://trial.medpath.com/news/031522bb7942b54d/granules-india-implements-digital-overhaul-following-fda-warning-over-manufacturing-violations 2026-04-09T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/a3fe74c1965abb66/car-t-cell-therapy-achieves-world-first-simultaneous-remission-of-three-autoimmune-diseases 2026-04-09T17:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/a347cf5c8928dc43/alpheus-medical-launches-phase-2b-trial-for-novel-glioblastoma-therapy-using-ultrasound-activated-drug-approach 2026-04-09T17:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/ab83150e26f9b6c6/sparian-biosciences-initiates-phase-1-trial-of-sbs-147-novel-oral-pain-drug-targeting-opioid-alternative 2026-04-09T17:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/557093a70a361c5f/thermo-fisher-scientific-and-seer-partner-with-singapore-s-precise-sg100k-for-large-scale-proteomics-study 2026-04-09T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/108bd8c39a5a1022/boston-oncology-secures-100m-licensing-deal-for-chinese-cancer-drugs-in-middle-east-and-north-africa 2026-04-09T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/f9de86eb3e8bc519/car-t-cell-therapy-achieves-complete-remission-in-woman-with-three-simultaneous-autoimmune-diseases 2026-04-09T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/a6a06a604ba576c3/jazz-pharmaceuticals-presents-new-epidiolex-behavioral-data-at-aan-2026-demonstrating-impact-beyond-seizure-control 2026-04-09T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/5d4e641811a92161/cures-within-reach-funds-five-drug-repurposing-trials-in-chicago-to-address-unmet-medical-needs 2026-04-09T17:04:40+00:00 hourly 0.9 https://trial.medpath.com/news/c6477d41adb8ba8f/galmed-develops-brain-penetrating-aramchol-formulation-for-parkinson-s-disease-and-synucleinopathies 2026-04-09T17:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/378549cc88ab963d/c4-therapeutics-and-roche-expand-partnership-with-1-billion-dac-collaboration 2026-04-09T13:08:07+00:00 hourly 0.9 https://trial.medpath.com/news/8b5c23b8bb4aee2a/gilead-exercises-option-for-kymera-s-kt-200-cdk2-degrader-triggering-45m-milestone-payment 2026-04-09T13:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/4086daba57e07bde/bdc-launches-150-million-life-sciences-venture-fund-to-address-early-stage-funding-gap-in-canada 2026-04-09T13:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/0694febf0300f22a/world-s-first-car-t-therapy-for-solid-tumors-set-to-launch-in-china 2026-04-09T09:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/3bf904214af3663b/triple-combination-pill-reduces-recurrent-stroke-risk-by-39-in-landmark-trident-trial 2026-04-09T05:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/db04cddfb1f49ccf/virica-biotech-and-fujifilm-biosciences-partner-to-enhance-aav-production-for-gene-therapy-manufacturing 2026-04-09T01:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/5945086b4234a560/proqr-partners-with-ginkgo-bioworks-to-accelerate-ai-driven-rna-editing-drug-discovery 2026-04-09T01:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/1f63b1cd1fc35501/avita-medical-secures-25-5m-barda-contract-for-emergency-burn-treatment-preparedness 2026-04-09T01:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/237f28cba5466546/neuroclues-secures-eur10-million-series-a-to-scale-ai-powered-eye-movement-biomarkers-for-neurological-diagnosis 2026-04-09T01:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/22719705d797b31d/aptar-digital-health-partners-with-enable-injections-to-develop-companion-digital-solution-for-enfuse-r-on-body-delivery-system 2026-04-09T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/07818c619b4c7f6f/takeda-s-anti-cd38-therapy-mezagitamab-achieves-91-response-rate-in-immune-thrombocytopenia-phase-ii-trial 2026-04-09T01:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/8ae572887cefb497/nih-funded-team-based-care-model-achieves-significant-blood-pressure-reduction-in-underserved-populations 2026-04-09T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/81dddef783899169/vanda-pharmaceuticals-initiates-thetis-trial-testing-nereus-for-glp-1-receptor-agonist-induced-vomiting 2026-04-09T01:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/bade260e015b061c/tavapadon-shows-promise-for-parkinson-s-disease-treatment-in-phase-3-trials 2026-04-08T21:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/17765b0f607a89a9/remedy-plan-therapeutics-strengthens-leadership-with-appointment-of-jotin-marango-as-cfo-and-cbo 2026-04-08T21:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/acec68a00de0f490/fshd-society-launches-industry-collaborative-to-accelerate-clinical-trial-development-for-rare-muscular-dystrophy 2026-04-08T21:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/9a78cbd8aff43312/trogenix-s-gene-therapy-achieves-83-complete-tumor-elimination-in-glioblastoma-model-nature-study-shows 2026-04-08T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/a3b069d19504db54/tae-life-sciences-achieves-100-complete-response-rate-in-head-and-neck-cancer-with-novel-bnct-platform 2026-04-08T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/8cfd7cdccca00d4c/transformer-base-editor-shows-promise-in-first-clinical-trial-for-b-thalassaemia-treatment 2026-04-08T21:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/66b2aebdef2418af/spermosens-advances-juno-checked-generation-3-fertility-diagnostic-system-through-clinical-validation 2026-04-08T21:03:40+00:00 hourly 0.9 https://trial.medpath.com/news/ed5bc2287d3f6b7a/chinese-cdmo-facilities-achieve-major-manufacturing-milestones-as-biologics-production-capacity-expands 2026-04-08T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/fcb79c000a393e92/23andme-identifies-genetic-variants-that-predict-glp-1-drug-response-and-side-effects 2026-04-08T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/5345eb3de556a999/bioporto-divests-antibody-business-for-10-5m-to-focus-on-ngal-biomarker-development 2026-04-08T17:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/cfe533258d5428d7/sidewinder-therapeutics-raises-137m-series-b-to-advance-next-generation-bispecific-adcs-for-cancer-treatment 2026-04-08T17:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/aa6af9e7f7d855d2/organogenesis-puraply-am-shows-significant-efficacy-in-diabetic-foot-ulcer-trial 2026-04-08T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/206a5905bf115109/stealth-biotherapeutics-appoints-david-a-brown-as-chief-scientific-officer-to-advance-mitochondrial-medicine-pipeline 2026-04-08T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/db69af8f320e6f2b/cortec-receives-fda-breakthrough-device-designation-for-brain-computer-interface-in-stroke-rehabilitation 2026-04-08T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/892dc2fafe86481d/duloxetine-fails-to-prevent-oxaliplatin-induced-peripheral-neuropathy-in-colorectal-cancer-patients 2026-04-08T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/99fd4bd7ceb31fab/modex-therapeutics-initiates-phase-1-trial-of-novel-tetravalent-covid-19-prevention-antibody-mdx2301 2026-04-08T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/36da39349880e3dd/fda-approves-radiesse-for-decollete-wrinkle-treatment-marking-first-biostimulator-for-face-and-body-use 2026-04-08T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/c8a99b3880cc0a06/supira-medical-receives-fda-approval-for-support-ii-pivotal-trial-of-next-generation-percutaneous-ventricular-assist-device 2026-04-08T17:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/e6fcbdd176dcc40c/waters-receives-fda-clearance-for-at-home-cervical-cancer-screening-kit 2026-04-08T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/2a11e140f918df17/purdue-pharma-s-novel-dual-mechanism-drug-tinostamustine-enters-phase-2-3-trial-for-glioblastoma 2026-04-08T17:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/ea8cd2da89c1c760/incyclix-bio-secures-5m-series-b-extension-to-advance-cdk2-inhibitor-inx-315-in-resistant-breast-and-ovarian-cancers 2026-04-08T13:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/205b645af983f93e/ani-pharmaceuticals-receives-fda-approval-for-generic-isosorbide-mononitrate-tablets 2026-04-08T13:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/f22e13624c803523/hku-and-grand-pharmaceutical-form-strategic-partnership-to-develop-novel-anti-infective-therapies 2026-04-08T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/4f56601ddd8da5eb/jeito-capital-closes-record-1-2-billion-fund-to-accelerate-european-biopharma-innovation 2026-04-08T09:07:45+00:00 hourly 0.9 https://trial.medpath.com/news/dc59abc8118223a6/route-92-medical-secures-50-million-growth-financing-to-expand-revolutionary-stroke-treatment-technology 2026-04-08T09:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/522aaa8533ea69d3/roosterbio-partners-with-minebio-to-expand-msc-and-exosome-manufacturing-solutions-in-china 2026-04-08T09:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/f905b5fb5f6eb5a8/huons-meditech-secures-nmpa-approval-for-premium-9pin-needle-in-china-s-aesthetic-market 2026-04-08T09:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/da6f2d8fd8b8e578/shionogi-secures-482-million-barda-contract-to-strengthen-u-s-biodefense-against-drug-resistant-bacterial-threats 2026-04-08T09:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/8fd67cce50c493e1/methylscan-blood-test-achieves-93-8-accuracy-in-detecting-four-cancer-types-through-novel-dna-methylation-analysis 2026-04-08T05:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/d8970feedb8a70a6/metformin-mimics-exercise-benefits-in-prostate-cancer-patients-through-metabolic-pathway-activation 2026-04-08T05:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/86bc950600d47ecf/neurotherapia-completes-phase-2a-trial-of-ntrx-07-for-alzheimer-s-disease-demonstrates-safety-and-target-engagement 2026-04-08T05:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/0f6dbffed266efad/ai-designed-drug-gatc-1021-shows-promise-for-opioid-use-disorder-in-landmark-pnas-study 2026-04-08T01:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/b154a2bddfe44c16/novel-actinium-225-radioconjugate-shows-promise-against-treatment-resistant-her2-positive-breast-cancer 2026-04-08T01:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/73a1fcb0bda13473/shionogi-s-cefiderocol-shows-68-clinical-cure-rate-against-highly-resistant-mbl-producing-enterobacterales-in-real-world-study 2026-04-08T01:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/75770666464f434c/salk-institute-receives-41-3m-arpa-h-award-to-advance-sonogenetics-as-drug-free-therapy-for-peripheral-neuropathy 2026-04-08T01:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/8886834fc7626fb2/insmed-discontinues-brensocatib-development-for-hidradenitis-suppurativa-after-phase-2b-trial-fails-to-meet-endpoints 2026-04-08T01:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/4b617742a15c3b73/hexembio-secures-10-4m-to-advance-blood-stem-cell-rejuvenation-therapy-for-cancer-treatment 2026-04-07T21:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/c777bea9055ff512/bioora-and-octane-biotech-partner-to-scale-car-t-manufacturing-using-automated-cocoon-platform 2026-04-07T21:08:04+00:00 hourly 0.9 https://trial.medpath.com/news/914315931a1d54b8/cornell-scientists-achieve-breakthrough-in-reversible-male-contraception-using-meiosis-disruption 2026-04-07T21:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/3aebb20e87e5ddc5/fda-approves-nexus-aortic-arch-stent-graft-system-for-minimally-invasive-treatment-of-complex-aortic-disease 2026-04-07T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/984355170bd5a4ab/merakris-therapeutics-reports-positive-interim-data-for-mtx-001-in-venous-leg-ulcers-advances-toward-late-stage-development 2026-04-07T17:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/bb26802d06330c44/inhibikase-therapeutics-initiates-phase-3-improve-pah-trial-for-novel-pulmonary-arterial-hypertension-treatment 2026-04-07T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/f1638e65a3d68b97/catalym-initiates-phase-2b-trial-of-visugromab-in-second-line-hepatocellular-carcinoma-treatment 2026-04-07T17:06:38+00:00 hourly 0.9 https://trial.medpath.com/news/4a2eb502af0b885e/singlomics-initiates-first-in-human-trial-of-dxp-106-novel-il-1rap-antibody-for-advanced-solid-tumors 2026-04-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/9870da6deb148c2f/alzheon-initiates-phase-1-trial-of-alz-507-next-generation-oral-alzheimer-s-drug-with-apoe4-corrector-mechanism 2026-04-07T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/6ed8f1786d7eae04/ac-immune-and-lilly-expand-tau-targeting-collaboration-with-chf-10-million-amendment-for-alzheimer-s-disease 2026-04-07T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/189a297b5da3b968/south-korea-approves-two-orphan-drugs-for-hiv-and-lung-cancer-patients-with-limited-treatment-options 2026-04-07T13:05:09+00:00 hourly 0.9 https://trial.medpath.com/news/a7b90eb43db44a77/allelica-partners-with-mass-general-brigham-for-proact-3-trial-testing-polygenic-risk-score-impact-on-cardiovascular-prevention 2026-04-07T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/d34618d6eca1f2df/abion-s-abn202-demonstrates-superior-anti-cancer-activity-over-trop2-targeting-adcs-in-preclinical-studies 2026-04-07T09:06:32+00:00 hourly 0.9 https://trial.medpath.com/news/2fa87f97cdf2360d/renovare-therapeutics-emerges-from-stealth-mode-with-33-5m-arpa-h-funding-for-osteoarthritis-regenerative-therapies 2026-04-07T09:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/026323d9a7c4feba/sanofi-s-dual-target-bispecific-lunsekimig-shows-promise-in-phase-2-respiratory-disease-studies 2026-04-07T09:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/06263769a5fb625c/invera-medical-receives-fda-clearance-for-novel-non-thermal-catheter-device-for-chronic-venous-disease-treatment 2026-04-07T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e02bcb48efc6961e/vanderbilt-center-partners-with-saravir-biopharma-to-develop-novel-monoclonal-antibody-therapy-for-measles 2026-04-07T01:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/d9677ba0d7facf9c/colorado-legislature-considers-exempting-orphan-drugs-from-state-pricing-caps-amid-industry-and-consumer-advocacy-debate 2026-04-07T01:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/11e1f91639256d53/artemilife-s-artemisia-infused-coffee-nears-phase-2-completion-for-prostate-cancer-maintenance-therapy 2026-04-07T01:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/23b88e971ae91895/merit-medical-acquires-view-point-medical-for-140-million-to-expand-breast-cancer-localization-portfolio 2026-04-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e5eb27671a78e7c/apple-s-studio-display-xdr-receives-fda-clearance-for-medical-imaging-applications 2026-04-06T21:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/136dc4239980273b/alar-pharmaceuticals-reports-breakthrough-phase-1-results-for-long-acting-ketamine-injectable-ala-3000-in-treatment-resistant-depression 2026-04-06T21:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/391f162ec38b3971/delfi-diagnostics-presents-five-studies-on-ai-driven-cfdna-platform-for-cancer-detection-and-monitoring-at-aacr-2026 2026-04-06T17:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/a2b215999e18d005/tenvie-therapeutics-initiates-first-in-human-trial-of-cns-penetrant-nlrp3-inhibitor-tnv262-for-obesity-and-cardiovascular-disease 2026-04-06T17:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/3e49ab11b14b0157/amgen-s-subcutaneous-tepezza-shows-77-response-rate-in-phase-3-thyroid-eye-disease-trial 2026-04-06T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/ecf563c6bf713ba7/iavi-initiates-first-in-human-trial-of-single-dose-marburg-virus-vaccine-candidate 2026-04-06T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/ee608ddea128c624/sk-life-science-to-present-comprehensive-cenobamate-data-and-patient-provider-communication-study-at-aan-2026 2026-04-06T17:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/a002bb6f54aca1a0/isatuximab-based-quadruplet-therapy-significantly-improves-mrd-negativity-in-newly-diagnosed-multiple-myeloma 2026-04-06T17:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/f873f3330dc08684/united-health-products-secures-fda-approval-for-new-clinical-study-partnership-to-advance-cellustat-hemostatic-gauze 2026-04-06T17:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/9e9f2f39b72b1388/university-of-edinburgh-researchers-identify-key-cellular-mechanism-driving-fibrosis-in-crohn-s-disease 2026-04-06T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/ce08478050a280ca/beacon-biosignals-raises-97-million-series-b-to-advance-at-home-eeg-brain-health-platform 2026-04-06T13:06:48+00:00 hourly 0.9 https://trial.medpath.com/news/f1e2a732f96869fd/stipple-bio-secures-100-million-series-a-to-advance-novel-adc-platform-targeting-tumor-specific-epitopes 2026-04-06T13:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/ac8b62a1cfe5b6ab/biocryst-pharmaceuticals-appoints-sandeep-m-menon-as-chief-research-and-development-officer 2026-04-06T13:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/a5fdfbcccfad5d0c/kowa-s-k-679-aduc-achieves-ultra-high-drug-loading-with-superior-tumor-distribution-in-preclinical-studies 2026-04-06T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/63762b81907abda4/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-adding-first-in-class-pws-treatment 2026-04-06T13:05:17+00:00 hourly 0.9 https://trial.medpath.com/news/3bb81e7f417cc423/profusa-expands-into-precision-diagnostics-with-30m-panomics-platform-acquisition-and-mayo-clinic-partnership 2026-04-06T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/1d9655964c2ce795/catheter-precision-presents-new-clinical-data-for-vivo-and-locket-systems-at-heart-rhythm-society-meeting 2026-04-05T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/1bf5a8af175672ce/indian-cancer-drug-manufacturers-seek-50-price-increase-as-platinum-costs-surge 2026-04-05T21:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/7a6a90c83a0c7b06/gene-therapy-restores-hearing-in-90-of-patients-with-genetic-deafness-in-landmark-clinical-trial 2026-04-05T05:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/a88289bc647fd8d4/large-scale-real-world-study-reveals-safer-second-line-diabetes-drug-options-for-elderly-patients 2026-04-05T01:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/f6461c723bfedaed/telomir-pharmaceuticals-secures-global-rights-to-telomir-1-through-teli-acquisition-advances-toward-triple-negative-breast-cancer-trial 2026-04-04T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fa7517249bb03e4b/fda-faces-pressure-to-reverse-peptide-safety-restrictions-under-kennedy-leadership 2026-04-04T01:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/06f3a3af6992cebc/takeda-announces-major-restructuring-with-247-job-cuts-in-massachusetts-to-fund-late-stage-pipeline 2026-04-03T21:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/e7bb56451a0c182d/gi-innovation-advances-cancer-immunotherapy-pipeline-with-asco-presentation-and-phase-2-trial-approval 2026-04-03T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/5d2a9c09b9ea957d/fda-recalls-over-3-million-eye-drop-bottles-due-to-sterility-concerns 2026-04-03T21:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/90abe48fc40c73ce/targeted-electroacupuncture-shows-promise-for-cognitive-symptoms-in-breast-cancer-survivors 2026-04-03T21:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/d7b58eec1f4d7d69/rhythm-pharmaceuticals-appoints-kim-popovits-to-board-of-directors-as-ed-mathers-departs 2026-04-03T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/79a5db1ff8844a42/texas-biomed-researchers-test-first-potential-measles-treatment-as-cases-surge-nationwide 2026-04-03T17:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/095d9f25f1f3cd6e/anthropic-acquires-ai-biotech-startup-coefficient-bio-for-400-million-to-advance-drug-discovery 2026-04-03T09:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/713d7de132f29677/oral-drug-n-ppg-shows-complete-prevention-of-kidney-stones-and-death-in-rare-disease-model 2026-04-03T05:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/f13fd88443b960c7/cipla-receives-fda-approval-for-generic-nintedanib-capsules-to-treat-idiopathic-pulmonary-fibrosis 2026-04-03T05:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/a64a016690c48dc8/high-dose-flu-vaccine-linked-to-55-lower-alzheimer-s-risk-in-adults-over-65 2026-04-03T05:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/5074f75994329ddc/regeneron-partners-with-trinetx-in-200-million-deal-to-access-300-million-patient-health-records-for-drug-discovery 2026-04-03T01:15:32+00:00 hourly 0.9 https://trial.medpath.com/news/9f4060525a44afbb/perceptive-discovery-expands-in-vitro-capabilities-with-five-fold-facility-increase-to-accelerate-oncology-drug-development 2026-04-02T21:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/2191fcc101febd71/st-jude-scientists-discover-how-to-restore-dendritic-cell-function-to-enhance-cancer-immunotherapy 2026-04-02T21:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/dc4185dc8f9b7efe/acurion-raises-4-3-million-to-advance-ai-powered-cancer-biomarker-detection-platform 2026-04-02T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/fe5be660ed56ab77/researchers-identify-three-existing-drugs-with-potential-for-epilepsy-treatment-through-computational-screening 2026-04-02T20:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/08f12ccc21cd3a61/novel-dual-hif-1-2-inhibitors-achieve-complete-tumor-remission-in-combination-with-immunotherapy 2026-04-02T17:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/aa814461a1f7bb91/mission-biocapital-opens-4-million-2026-platinum-program-for-global-biotech-startups 2026-04-02T17:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/f0f2e0fc53761f28/panoramic-health-and-west-coast-kidney-institute-launch-specialized-research-institute-for-cardio-renal-metabolic-trials 2026-04-02T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/604e6a0f377257c1/neutrolis-reports-positive-phase-1a-results-for-first-in-class-net-targeting-therapy-ntr-1011 2026-04-02T17:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/c92671f7901548f8/glycomine-completes-enrollment-in-phase-2b-polar-study-of-glm101-for-rare-genetic-disorder-pmm2-cdg 2026-04-02T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/d17ab26d098a8ea1/earendil-labs-initiates-phase-iia-trial-of-half-life-extended-anti-tl1a-antibody-hxn-1001-for-ulcerative-colitis 2026-04-02T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/ce33c8e62189755f/palleon-pharmaceuticals-to-present-first-in-class-b7-h3-targeted-sialidase-hlx316-e-688-at-aacr-2026 2026-04-02T17:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/34a9e87311d59214/cellcarta-and-pillar-biosciences-form-strategic-partnership-to-accelerate-ngs-tumor-profiling-for-oncology-trials 2026-04-02T17:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/6e17ecb59d650ab0/oncotelic-therapeutics-partners-with-techforce-robotics-to-commercialize-ai-enhanced-gmp-manufacturing-platform 2026-04-02T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/07c8e85a6564fe4f/canwell-pharma-receives-fda-clearance-for-can016-dual-payload-adc-in-her2-positive-tumors 2026-04-02T17:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/8b67a6ef4993f5ae/merck-kgaa-completes-acquisition-of-jsr-chromatography-business-to-expand-protein-a-purification-capabilities 2026-04-02T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/8d21d9b11419256c/triple-hair-initiates-phase-iii-trial-for-th07-triple-combination-therapy-in-male-pattern-baldness 2026-04-02T17:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/9e02a7e57846a284/context-therapeutics-receives-fda-fast-track-designation-for-ctim-76-in-platinum-resistant-ovarian-cancer 2026-04-02T13:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/71885a60057add83/immunovant-s-batoclimab-fails-phase-3-thyroid-eye-disease-trials-despite-early-promise 2026-04-02T13:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/265255bb69199f77/priovant-launches-phase-2b-3-trial-for-brepocitinib-in-lichen-planopilaris-targeting-rare-scarring-hair-loss-disorder 2026-04-02T13:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/dda8158dc3be759d/pfizer-biontech-halt-covid-19-vaccine-trial-for-adults-50-64-due-to-enrollment-challenges 2026-04-02T13:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/e56a992f3e283ed6/merck-initiates-pivotal-phase-2b-3-trial-for-novel-bispecific-antibody-mk-8748-in-wet-age-related-macular-degeneration 2026-04-02T13:04:05+00:00 hourly 0.9 https://trial.medpath.com/news/6a4178c63d3139b1/avencell-doses-first-patient-with-world-s-first-crispr-engineered-dual-targeting-allogeneic-car-t-therapy 2026-04-02T13:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/42b5c13d5cecdde3/middle-east-disruption-impacts-6-7-of-global-clinical-trials-threatening-drug-development-pipeline 2026-04-02T13:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/554ff96c16d54581/aneuvo-secures-fda-clearance-for-exastim-spinal-cord-stimulation-system-following-22m-series-c 2026-04-02T11:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/f546b055a7d40996/medibeacon-s-transdermal-kidney-function-monitor-receives-european-ce-mark-certification 2026-04-02T09:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/6e44441ef905cf82/generare-secures-eur20m-series-a-to-unlock-cryptic-molecular-chemistry-from-microbial-genomes 2026-04-02T09:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/b5c6f52bcfb545ed/fda-approves-second-glp-1-pill-for-weight-loss-with-fewer-usage-restrictions 2026-04-02T05:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/139a1b9a73a3d329/digital-twin-hearts-show-100-success-rate-in-first-clinical-trial-for-ventricular-tachycardia-ablation 2026-04-02T01:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/0b04aa54e3eaa7d4/uspto-introduces-new-pre-order-procedure-to-address-patent-reexamination-gaming-tactics 2026-04-02T01:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/18493baa9387ad75/onemednet-partners-with-onco-innovations-to-accelerate-pnkp-inhibitor-development-using-ai-powered-real-world-data 2026-04-02T01:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/6e9ed8e72df0eec8/dulaglutide-shows-promise-for-coronary-plaque-stabilization-in-type-2-diabetes-patients 2026-04-02T01:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/d55dc1fcc3db52b7/eli-lilly-ceo-opposes-congressional-codification-of-trump-s-most-favored-nation-drug-pricing-deals 2026-04-02T01:08:26+00:00 hourly 0.9 https://trial.medpath.com/news/f5e74f67f048fa12/mirtazapine-shows-promise-for-methamphetamine-use-disorder-in-phase-3-trial 2026-04-02T01:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/08ee4cbdb3a507c2/fore-biotherapeutics-receives-first-ever-breakthrough-therapy-designation-for-high-grade-glioma-targeted-therapy 2026-04-02T01:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/b9d2be1d4f23f60b/redwood-ai-partners-with-ubc-to-develop-novel-alzheimer-s-therapeutics-targeting-nudt5-protein 2026-04-02T01:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/920d128f891eb52a/uk-universities-develop-revolutionary-stem-cell-therapy-for-hirschsprung-disease 2026-04-01T21:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/02c779b853d50b42/marksans-pharma-receives-fda-approval-for-generic-benzonatate-capsules-shares-surge-9 2026-04-01T21:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/f17ad50f90e145ca/pulmobiomed-receives-ce-mark-for-first-deep-lung-breath-sampling-device-addressing-40-year-clinical-challenge 2026-04-01T21:09:48+00:00 hourly 0.9 https://trial.medpath.com/news/add5c7592d3f6ca3/syneron-bio-secures-150m-series-b-to-advance-macrocyclic-peptide-drug-discovery-platform 2026-04-01T21:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/f9f5b3898be96de8/lord-trial-shows-active-surveillance-may-be-safe-alternative-to-surgery-for-low-risk-dcis 2026-04-01T21:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/c9287c4223d884e9/phase-3-c-diff-vaccine-trial-launches-at-university-of-washington-to-protect-high-risk-older-adults 2026-04-01T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/46ce707782d337e7/orion-corporation-appoints-berkeley-vincent-as-executive-vice-president-of-innovative-medicines 2026-04-01T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/42ca51829a894c66/geropharm-advances-biosimilar-development-with-phase-i-trials-for-novo-nordisk-s-diabetes-combination-therapy 2026-04-01T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/54bcba7672410dd7/biontech-to-close-singapore-manufacturing-plant-by-february-2027-amid-revenue-decline 2026-04-01T17:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/c0cdb5b628b8ad0d/anixa-biosciences-advances-breast-cancer-vaccine-to-phase-2-following-successful-phase-1-trial 2026-04-01T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/b14cc3853d340301/thermo-fisher-scientific-launches-next-generation-cell-line-development-platform-to-accelerate-biologics-manufacturing 2026-04-01T17:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/4851263bbf95089c/vascarta-s-topical-curcumin-gel-vas-101-shows-significant-pain-reduction-in-knee-osteoarthritis-phase-1b-trial 2026-04-01T17:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/91b06f69ad8f486a/tango-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-precision-oncology-pipeline 2026-04-01T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/816b9ae7b1e965a8/who-recommended-antibiotics-effective-in-only-25-of-neonatal-sepsis-cases-in-low-income-countries 2026-04-01T17:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/28cf4640c4280bba/fda-delays-nicotine-pouch-approvals-amid-youth-addiction-concerns 2026-04-01T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/15d3068f19754298/nih-researchers-develop-novel-opioid-dfnz-with-potent-pain-relief-and-reduced-addiction-risk 2026-04-01T17:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/6410eed13317f186/scientists-develop-smart-dna-drug-system-that-targets-cancer-cells-with-computer-like-precision 2026-04-01T13:22:46+00:00 hourly 0.9 https://trial.medpath.com/news/e60294c3d3de77f2/symeres-and-ambagon-partner-to-develop-molecular-glue-therapeutics-for-colorectal-cancer 2026-04-01T13:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/a94ada04c7731a61/bd-expands-ai-powered-medication-dispensing-system-to-european-market 2026-04-01T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/0d8227c60ea6cd0b/fosun-pharma-receives-nmpa-approval-for-phase-1-trial-of-hlx319-biosimilar-for-breast-cancer-treatment 2026-04-01T13:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/f81bcb83b9af1e04/flagship-pioneering-partners-with-aws-to-accelerate-ai-driven-drug-discovery-across-portfolio-companies 2026-04-01T13:21:40+00:00 hourly 0.9 https://trial.medpath.com/news/f46094ab0cf50e52/prism-als-initiative-launches-to-address-critical-gap-in-als-drug-discovery-through-patient-derived-stem-cell-models 2026-04-01T09:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/178bf711cc1f9752/askbio-completes-enrollment-in-phase-2-gene-therapy-trial-for-heart-failure 2026-04-01T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/756e772bcddd0275/nj-bio-and-ajinomoto-bio-pharma-services-partner-to-advance-antibody-drug-conjugate-development-through-ajicaptm-platform-integration 2026-04-01T01:08:41+00:00 hourly 0.9 https://trial.medpath.com/news/244e90607ae37172/inhibitor-therapeutics-advances-itraconazole-program-for-gorlin-syndrome-with-novel-amorphous-formulation 2026-04-01T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/18305e47ed895607/kenya-launches-lenacapavir-hiv-prevention-program-but-access-barriers-persist-in-high-risk-communities 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/be7cea8178fcf111/xbrane-resubmits-ranibizumab-biosimilar-application-to-fda-following-manufacturing-site-corrections 2026-04-01T01:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/631e1201ce906316/lg-chem-acquires-worldwide-rights-to-first-in-class-p53-y220c-cancer-drug-fmc-220 2026-04-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/afd27d0dc5bb4d4f/pelthos-therapeutics-initiates-phase-1b-2a-trial-of-ct2000-eye-drops-for-chronic-ocular-pain-in-dry-eye-disease 2026-03-31T21:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/a11d55d1484b1f7b/cancervax-achieves-breakthrough-in-targeted-lipid-nanoparticle-delivery-avoiding-liver-toxicity-in-mouse-studies 2026-03-31T21:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/558e67ec0fdc4107/fda-grants-first-ever-approval-for-cerebral-venous-stent-to-treat-severe-idiopathic-intracranial-hypertension 2026-03-31T21:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/12fc1996a95810b6/amylin-drug-development-surges-with-19-billion-investment-as-nearly-40-programs-target-obesity-treatment 2026-03-31T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/5983cc2b37c1db32/adcytherix-doses-first-patient-in-phase-1-trial-of-adcx-020-marking-transition-to-clinical-stage-company 2026-03-31T17:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/3998ca8a3333304e/tippingpoint-biosciences-secures-4-5m-to-target-undruggable-epigenetic-interfaces-in-pediatric-brain-cancer 2026-03-31T17:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/4daa8506f002ba88/pheast-therapeutics-advances-phst001-anti-cd24-antibody-into-phase-1b-combination-trials 2026-03-31T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/9f466338cbb3937a/hemogenyx-pharmaceuticals-completes-manufacturing-tech-transfer-for-hg-ct-1-car-t-therapy-expands-clinical-trial-to-pediatric-aml-patients 2026-03-31T17:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/9f1321ca1b73c044/ambros-therapeutics-secures-key-patent-for-precision-medicine-approach-to-treating-complex-regional-pain-syndrome 2026-03-31T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/d6b7d6dc0610a946/enveda-s-env-294-shows-85-easi-reduction-in-phase-1b-atopic-dermatitis-trial 2026-03-31T17:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/e7955a5a88d00424/immunitybio-secures-100-million-in-financing-to-support-global-expansion-of-anktiva-immunotherapy 2026-03-31T17:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/6368d784a0e5b5a4/tarsus-pharmaceuticals-initiates-phase-2-trial-for-first-oral-lyme-disease-prevention-therapy 2026-03-31T17:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/4ec5a036b249b56c/fda-expands-marketing-crackdown-to-cancer-biologics-targets-four-major-companies-over-misleading-survival-claims 2026-03-31T17:05:53+00:00 hourly 0.9 https://trial.medpath.com/news/eeff492994f8bf1a/proxygen-appoints-chiara-conti-as-cso-to-accelerate-molecular-glue-platform-into-clinical-development 2026-03-31T17:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/c4fe737b70a2d8b5/infinimmune-partners-with-merck-in-838-million-antibody-discovery-deal 2026-03-31T17:05:44+00:00 hourly 0.9 https://trial.medpath.com/news/2d9d4a853ab19b4f/cellcentric-launches-pivotal-phase-2-trial-of-inobrodib-combination-for-relapsed-multiple-myeloma 2026-03-31T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/e212c39eb7164204/final-arrow-study-data-shows-pralsetinib-achieves-70-response-rate-in-ret-nsclc-with-durable-survival-outcomes 2026-03-31T17:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/a1002cea9633d3dd/restore-robotics-expands-fda-cleared-robotic-instrument-portfolio-with-two-additional-da-vinci-xi-clearances 2026-03-31T17:04:23+00:00 hourly 0.9 https://trial.medpath.com/news/6b27fc3dbc289cfa/gan-lee-s-once-weekly-insulin-gzr4-demonstrates-superior-efficacy-in-phase-3-trials 2026-03-31T17:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/d5696e95885b3275/i-lumen-scientific-receives-fda-ide-approval-to-expand-bioelectric-stimulation-trial-for-dry-amd-to-u-s 2026-03-31T17:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/d623e85a2d3a4c62/hong-kong-launches-primary-evaluation-system-for-independent-drug-approval 2026-03-31T17:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/045bc751db91b26d/eli-lilly-acquires-centessa-pharmaceuticals-for-up-to-7-8-billion-to-expand-sleep-disorder-portfolio 2026-03-31T13:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/41386345f7911dfe/semarion-secures-3-8m-to-scale-cell-based-drug-discovery-platform 2026-03-31T13:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/bc6e069930b8e3f3/biogen-acquires-apellis-for-5-6-billion-expanding-immunology-and-rare-disease-portfolio 2026-03-31T13:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/557522bdfeef929b/astrazeneca-s-efzimfotase-alfa-shows-promise-in-phase-iii-hypophosphatasia-trials-with-mixed-results 2026-03-31T13:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/5af7ca0c70c600a2/sirpad-trial-demonstrates-superior-efficacy-of-sirolimus-coated-balloons-in-peripheral-artery-disease-treatment 2026-03-31T13:04:45+00:00 hourly 0.9 https://trial.medpath.com/news/c7953195b1d06ca5/fda-grants-orphan-drug-designation-to-signablok-s-trem-1-inhibitor-for-retinopathy-of-prematurity 2026-03-31T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/45db598ae7a9e5a8/signadori-bio-appoints-dr-selwyn-ho-as-ceo-to-advance-novel-monocyte-immunotherapy-platform 2026-03-31T09:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/adb981b3573db7ab/bioversys-partners-with-hackensack-meridian-health-to-advance-novel-ansamycin-antibiotics-for-non-tuberculous-mycobacteria 2026-03-31T09:04:15+00:00 hourly 0.9 https://trial.medpath.com/news/3b1e1d4334068dd6/4basebio-expands-manufacturing-capacity-with-new-26500-square-foot-cambridge-facility-to-meet-growing-synthetic-dna-demand 2026-03-31T09:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/d3423864471bfb5e/toppan-holdings-launches-us-subsidiary-to-advance-personalized-cancer-medicine-using-3d-cell-culture-technology 2026-03-31T09:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/f1412d17ded63dab/crown-reserve-acquisition-corp-i-and-carvix-announce-1-0-billion-business-combination-agreement 2026-03-31T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/f7cfa5c8130d9d0d/everest-medicines-reports-promising-first-in-human-data-for-personalized-mrna-cancer-vaccine-evm16 2026-03-31T05:04:29+00:00 hourly 0.9 https://trial.medpath.com/news/76e87737db953d07/fluvoxamine-shows-promise-for-long-covid-fatigue-in-international-clinical-trial 2026-03-31T01:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/9591432381f15bb3/neurocrine-biosciences-acquires-soleno-therapeutics-for-2-9-billion-in-rare-disease-expansion 2026-03-31T01:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/149dcab68958c148/haemonetics-receives-fda-approval-for-expanded-vascade-mvp-xl-labeling-to-support-advanced-atrial-fibrillation-procedures 2026-03-31T01:04:28+00:00 hourly 0.9 https://trial.medpath.com/news/7e75d2905d3fb0ed/4dmedical-secures-ce-mark-for-revolutionary-ct-vqtm-lung-imaging-technology-opens-european-market 2026-03-31T01:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/1b15fc7dc503003f/sharp-quality-leader-advocates-for-supply-chain-wide-quality-culture-beyond-compliance 2026-03-31T00:46:03+00:00 hourly 0.9 https://trial.medpath.com/news/f58d2ebd112eceb3/neural-progenitor-cell-transplants-show-promise-for-spinal-cord-repair-through-motor-circuit-reconnection 2026-03-30T21:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/04045d6ba0abddba/butterfly-network-receives-first-fda-clearance-for-ai-powered-gestational-age-ultrasound-tool 2026-03-30T21:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/ebd08144e4f7de71/triglyceride-lowering-drug-olezarsen-fails-to-reduce-arterial-plaque-despite-60-triglyceride-reduction 2026-03-30T21:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/4998553d63cf3bf5/merck-s-oral-cholesterol-drug-enlicitide-shows-64-6-ldl-reduction-in-late-stage-trial 2026-03-30T21:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/5989e20b6347e7b9/smart-decision-trial-shows-beta-blocker-discontinuation-safe-for-low-risk-post-mi-patients 2026-03-30T21:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/1b019360dda48d07/ap-biosciences-and-tasly-amend-collaboration-to-accelerate-global-development-of-dual-target-cancer-therapy-ap505 2026-03-30T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/6d798b4d3b835710/blackstone-closes-record-6-3-billion-life-sciences-fund-largest-private-investment-vehicle-in-sector-history 2026-03-30T21:12:42+00:00 hourly 0.9 https://trial.medpath.com/news/46040b9e00bd65c1/university-of-arizona-launches-12-million-phase-3-trial-testing-rapamycin-for-healthy-aging 2026-03-30T21:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/9ed10070e15d929d/bullfrog-ai-secures-major-commercial-agreement-with-top-5-pharma-company-for-ai-driven-depression-drug-discovery 2026-03-30T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/5b72dc3f1ca44f1b/hengrui-pharma-and-braveheart-bio-report-promising-phase-2-results-for-next-generation-cardiac-myosin-inhibitor-in-obstructive-hypertrophic-cardiomyopathy 2026-03-30T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/2be52d2539d6c0fd/j-j-s-spravato-shows-sustained-antidepressant-effects-six-months-after-treatment-discontinuation-in-real-world-study 2026-03-30T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/17cc1bad9b61cfcd/tartan-hf-trial-reveals-one-in-four-diabetics-has-undiagnosed-heart-failure 2026-03-30T17:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/8273cd04d2203e3a/fda-clears-ultragenyx-ind-application-for-ux016-to-treat-rare-gne-myopathy 2026-03-30T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/58ae101fd1d78b41/calliditas-therapeutics-presents-new-nefigard-trial-data-supporting-nefecon-s-gut-targeted-mechanism-in-iga-nephropathy 2026-03-30T17:08:12+00:00 hourly 0.9 https://trial.medpath.com/news/f51408df1fbffcbe/emboline-s-emboliner-system-achieves-superior-debris-capture-in-pivotal-tavr-protection-trial 2026-03-30T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/fae8d7287968b2e9/vor-bio-initiates-global-phase-3-trial-of-telitacicept-for-primary-sjogren-s-disease 2026-03-30T13:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/ca30eba0f535281c/novartis-and-abbvie-sue-washington-state-over-new-340b-drug-pricing-transparency-law 2026-03-30T13:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/cfee251240a0e9a0/prilenia-and-ferrer-launch-pivotal-phase-3-trial-of-pridopidine-for-rapidly-progressive-als 2026-03-30T13:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/7dbe17c271d8be7c/dompe-initiates-phase-2-trial-of-intranasal-ngf-for-spastic-cerebral-palsy-in-italy 2026-03-30T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/5ab4b84664f3b3cf/boston-scientific-receives-fda-clearance-for-asurys-fluid-management-system-to-address-kidney-stone-treatment-challenges 2026-03-30T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/bc5f137cee0cb313/harmonicare-receives-fda-approval-for-fgfr2-3-inhibitor-absk061-clinical-trial-in-pediatric-achondroplasia 2026-03-30T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/2811a00f123cc4d3/nanobiotix-reports-promising-early-data-from-phase-2-lung-cancer-trial-of-jnj-1900-radioenhancer 2026-03-30T09:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/e95ed08bd8d78b25/roche-launches-cobas-mpx-e-assay-revolutionary-4-in-1-blood-screening-test-enhances-global-blood-supply-safety 2026-03-30T09:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/06664bb82d2a65f1/algorae-pharmaceuticals-advances-ai-driven-drug-discovery-with-second-peter-maccallum-cancer-centre-collaboration 2026-03-30T09:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/072493bbaa102004/revolutionary-microneedle-patch-enables-non-invasive-immune-system-monitoring 2026-03-30T01:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/6589bcb206854ded/first-placebo-controlled-trial-shows-angioplasty-significantly-reduces-angina-in-chronic-total-occlusion-patients 2026-03-30T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/e74595e9dcfe891b/spirit-hf-trial-shows-no-benefit-and-safety-concerns-for-spironolactone-in-heart-failure-with-preserved-ejection-fraction 2026-03-29T21:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/d12f326ff5a606b8/real-world-study-confirms-safety-of-biologic-therapies-in-asthma-shows-reduced-pneumonia-risk 2026-03-29T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/5c3f5a7344093aea/bristol-myers-squibb-s-cobenfy-shows-stable-transition-profile-in-phase-4-schizophrenia-trial 2026-03-29T17:07:05+00:00 hourly 0.9 https://trial.medpath.com/news/8ae45e31b04ea21f/yingen-bio-s-her2-adc-db-1303-receives-marketing-approval-acceptance-in-china-for-breast-cancer-treatment 2026-03-29T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/dd2b42f75ba797f0/key-phase-3-trials-from-moderna-sarepta-and-krystal-biotech-set-to-drive-2026-biotech-performance 2026-03-29T17:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/5f341e93278481cf/fast-iii-trial-shows-non-invasive-vffr-technology-matches-gold-standard-ffr-for-coronary-revascularization-guidance 2026-03-29T17:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/7d665b5be0462c12/eli-lilly-abandons-pbs-negotiations-for-mounjaro-leaving-450000-australians-without-subsidized-access 2026-03-29T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/0912570e237c0850/grand-pharmaceutical-secures-china-approval-for-eye-treatment-gpn01768-advances-migraine-drug-to-phase-ii 2026-03-29T13:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/314713d3b3c7c951/remegen-secures-nmpa-approval-for-phase-i-iia-trial-of-bispecific-adc-rc288-in-solid-tumors 2026-03-29T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/de90ad1dae4565e1/tonlamarsen-shows-promise-in-resistant-hypertension-despite-mixed-phase-2-results 2026-03-29T01:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/359852b0821038b4/repatha-reduces-first-major-cardiovascular-events-by-31-in-high-risk-patients-without-significant-atherosclerosis 2026-03-29T01:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/37b6c377351e4f57/tens-therapy-shows-sustained-pain-relief-for-fibromyalgia-patients-in-large-real-world-trial 2026-03-28T21:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/2017aa34e244de22/anumana-receives-fda-clearance-for-first-ecg-ai-algorithm-to-detect-early-pulmonary-hypertension 2026-03-28T21:10:39+00:00 hourly 0.9 https://trial.medpath.com/news/7d1a82495d9b14dd/incyte-s-povorcitinib-shows-71-response-rate-in-late-stage-hidradenitis-suppurativa-trials 2026-03-28T21:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/1220bb4fd5b1bfa2/boston-scientific-s-ekos-system-shows-superior-outcomes-in-pulmonary-embolism-treatment 2026-03-28T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/0922737f74b2469c/fda-approves-bayer-s-lynkuet-as-first-nonhormonal-menopause-treatment-for-hot-flashes 2026-03-28T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/fdf37944da1f6613/impella-cp-heart-pump-fails-to-reduce-infarct-size-in-major-stemi-trial 2026-03-28T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/38dd39978743b7e4/champion-af-trial-shows-watchman-flx-device-non-inferior-to-blood-thinners-for-stroke-prevention-in-atrial-fibrillation 2026-03-28T17:06:52+00:00 hourly 0.9 https://trial.medpath.com/news/59efb8fdc7257fe7/iterum-therapeutics-seeks-court-led-dissolution-following-failed-fundraising-and-orlynvah-sales-struggles 2026-03-28T13:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/7909ccace92c5ef5/university-of-manchester-receives-ps1-million-to-develop-snail-inspired-soft-robots-for-bowel-cancer-drug-delivery 2026-03-28T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/14385bf5e423aa94/biocon-appoints-shreehas-tambe-as-ceo-following-major-organizational-restructuring 2026-03-28T05:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/ccf576fe05510c83/bamf-health-advances-theranostic-treatment-for-colorectal-cancer-in-west-michigan-clinical-trials 2026-03-28T01:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/f03adf3c8bf02c97/pig-semen-derived-eye-drops-show-promise-for-retinoblastoma-treatment-in-preclinical-studies 2026-03-28T01:05:57+00:00 hourly 0.9 https://trial.medpath.com/news/bd0c0e91c301c506/sun-pharma-s-fibromun-and-nidlegy-face-mixed-clinical-trial-results-in-cancer-studies 2026-03-28T01:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/bc2beccd0a6379c0/researchers-develop-wireless-implantable-device-to-solve-oxygen-challenge-in-cell-based-drug-delivery 2026-03-28T01:04:54+00:00 hourly 0.9 https://trial.medpath.com/news/29169d2b3645246d/low-dose-ct-screening-reduces-lung-cancer-mortality-by-55-in-non-risk-based-population 2026-03-27T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/09dce9349144c966/nkarta-secures-fda-approval-for-outpatient-car-nk-cell-therapy-administration-in-autoimmune-disease-trials 2026-03-27T17:12:17+00:00 hourly 0.9 https://trial.medpath.com/news/8cd8beebb13aa8ce/fda-clears-phase-1-pediatric-cns-cancer-trial-for-star-001-combination-therapy 2026-03-27T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/3bfa14482b654101/northwestern-team-develops-implantable-living-pharmacy-device-that-produces-multiple-drugs-simultaneously 2026-03-27T17:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/29031bb17ad0f4d3/ema-recommends-approval-of-amgen-s-tarlatamab-for-relapsed-small-cell-lung-cancer 2026-03-27T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/60f7bff64e59dae7/otsuka-acquires-transcend-therapeutics-for-1-2-billion-to-advance-ptsd-treatment-with-breakthrough-therapy-tsnd-201 2026-03-27T17:06:20+00:00 hourly 0.9 https://trial.medpath.com/news/1fa217d6a376edef/arletta-pharma-s-lybridotm-shows-statistically-significant-improvement-in-female-sexual-dysfunction-phase-ii-trial 2026-03-27T17:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/387b8aa0d475a0a6/prf-technologies-advances-ocuring-k-intraocular-ring-for-cataract-surgery-through-phase-i-safety-studies 2026-03-27T13:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/a2b07aebf2a71043/novartis-acquires-excellergy-for-up-to-2-billion-to-strengthen-immunology-portfolio 2026-03-27T13:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/6ab63b944169e296/astrazeneca-s-tozorakimab-achieves-primary-endpoints-in-phase-iii-copd-trials-demonstrating-significant-reduction-in-exacerbations 2026-03-27T13:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/f8daec2fd9fc05ed/espresso-trial-challenges-more-therapy-earlier-paradigm-in-stroke-rehabilitation 2026-03-27T09:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/3ba0ef1883a16d4b/intelligent-bio-solutions-secures-eighth-european-patent-for-advanced-fingerprint-drug-testing-technology 2026-03-27T05:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/aaf17f68926a6464/pinnacle-medicines-raises-89-million-series-b-to-advance-oral-peptide-therapeutics-into-clinical-trials 2026-03-27T05:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/aad23eee71214baf/lunai-bioworks-acquires-blood-brain-barrier-delivery-platform-in-20m-deal-to-advance-alzheimer-s-therapeutics 2026-03-27T01:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/bc0c14dc0c838b30/allogene-therapeutics-reports-promising-data-for-off-the-shelf-car-t-therapy-in-b-cell-lymphoma 2026-03-27T01:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/a715ccaf5fbc3556/vivani-medical-advances-npm-139-semaglutide-implant-toward-phase-1-trial-following-successful-preclinical-data 2026-03-27T01:06:36+00:00 hourly 0.9 https://trial.medpath.com/news/b0e2bb4797d30f1f/fda-approves-novo-nordisk-s-awiqli-first-once-weekly-basal-insulin-for-type-2-diabetes 2026-03-27T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/a16e8e649f6615ac/metformin-s-anti-diabetic-effects-linked-to-brain-mechanism-involving-rap1-protein 2026-03-27T01:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/54f1af2fe8a532ad/rubedo-life-sciences-reports-positive-phase-1-results-for-first-in-class-gpx4-modulator-rls-1496-in-dermatological-conditions 2026-03-27T01:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/ebbb9f935384f9f1/humacyte-appoints-rick-mcelheny-as-senior-vp-of-business-development-to-accelerate-bioengineered-tissue-partnerships 2026-03-26T21:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/bdfcd62e697bcf46/herbalife-acquires-personalized-supplement-startup-bioniq-for-up-to-150m-to-scale-data-driven-nutrition 2026-03-26T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/6f210520435725da/pulmatrix-and-eos-senolytix-announce-19-million-merger-to-advance-anti-aging-mitochondrial-therapies 2026-03-26T21:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/1fae1096e4903313/oig-approves-medicare-cost-sharing-subsidies-for-heart-failure-device-clinical-trial 2026-03-26T17:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/5d847515219c0f31/eurofins-viracor-launches-rapid-car-t-cell-monitoring-assay-for-obe-cel-therapy 2026-03-26T17:09:31+00:00 hourly 0.9 https://trial.medpath.com/news/0e1ecea8eb67a17e/quantum-biopharma-appoints-principal-investigator-for-phase-2-multiple-sclerosis-trial-of-lucid-ms 2026-03-26T17:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/0dba9b21e70c4bc4/made-scientific-partners-with-njit-to-launch-graduate-cell-and-gene-therapy-bioprocessing-program 2026-03-26T17:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/93f5cb40983ac922/kodiak-sciences-zenkuda-achieves-primary-endpoint-in-phase-3-diabetic-retinopathy-trial 2026-03-26T17:07:29+00:00 hourly 0.9 https://trial.medpath.com/news/35e4c19366c9ab3c/sino-biopharm-reports-strong-2025-results-with-26-2-growth-in-innovative-drug-sales 2026-03-26T17:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/3a3e47307d53888e/kamada-secures-fda-approval-for-san-antonio-plasma-collection-center-expanding-specialty-plasma-production-capacity 2026-03-26T17:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/5ab713bac040dd01/kodiak-sciences-zenkuda-achieves-62-5-response-rate-in-phase-3-glow2-diabetic-retinopathy-trial 2026-03-26T17:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/d33798440177deb6/meiragtx-receives-fda-breakthrough-therapy-designation-for-gene-therapy-treating-radiation-induced-dry-mouth 2026-03-26T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/a1385c2fb563f56b/mytomorrows-partners-with-spanish-academic-hospital-to-deploy-ai-powered-clinical-trial-matching-system 2026-03-26T17:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/31d3dc0abac71957/bioptimus-launches-stela-world-s-largest-spatial-biology-atlas-to-power-ai-driven-precision-medicine 2026-03-26T13:08:15+00:00 hourly 0.9 https://trial.medpath.com/news/05efe1de2757c0d5/invivoscribe-achieves-ivdr-class-c-certification-for-b-cell-lymphoma-diagnostic-assay-in-europe 2026-03-26T13:08:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda168e1a5603bd5/vagus-nerve-stimulation-shows-promise-for-ptsd-treatment-in-clinical-trials 2026-03-26T13:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/e17da834eb1734a0/tonix-pharmaceuticals-initiates-phase-1-study-of-tnx-1900-intranasal-oxytocin-for-migraine-treatment 2026-03-26T13:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/28354a409cfb594c/norgine-receives-swiss-approval-for-pedmarqsi-first-treatment-to-prevent-cisplatin-induced-hearing-loss-in-children 2026-03-26T13:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/10b4f445a8a2d8dc/innate-pharma-advances-oncology-pipeline-with-phase-3-trial-plans-and-promising-adc-data 2026-03-26T09:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/13647a371ff6881a/imperative-care-launches-clear-it-study-to-establish-clinical-standards-for-peripheral-thromboembolism-treatment 2026-03-26T09:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/33996c66a242c6e8/sk-biopharmaceuticals-launches-cenobamate-in-china-marking-major-milestone-for-epilepsy-treatment 2026-03-26T09:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/263c648bd3b7508a/hmh-holding-completes-210-4-million-ipo-pricing-for-drilling-equipment-technology 2026-03-26T05:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/7155ccac303c5ac6/purple-biotech-partners-with-converge-bio-to-accelerate-ai-driven-tri-specific-antibody-development 2026-03-26T05:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/96fac63069ed5bcf/brightgene-s-oral-glp-1-gip-dual-agonist-bgm0504-shows-promising-weight-loss-results-in-phase-1-trials 2026-03-26T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/0d95595e863aa02c/elmed-life-sciences-secures-2-7m-series-a-to-expand-microbiome-based-healthcare-solutions 2026-03-26T05:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/a33a2fb780383c9c/hrt-patches-show-equal-efficacy-to-injections-for-locally-advanced-prostate-cancer-treatment 2026-03-26T01:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/9e085049186d8d44/methylphenidate-may-reduce-psychosis-risk-in-children-with-adhd-large-finnish-study-shows 2026-03-26T01:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/12ee91e4b091fe46/breakthrough-oral-drug-delivery-technology-enables-depression-treatment-through-fat-absorption-pathways 2026-03-25T21:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/345c8d474a271bf7/blood-pressure-drug-telmisartan-shows-promise-in-enhancing-cancer-treatment-effectiveness 2026-03-25T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/4cfdc1f033cd5e81/beyondspring-s-plinabulin-shows-promise-in-overcoming-immunotherapy-resistance-in-nsclc 2026-03-25T17:19:55+00:00 hourly 0.9 https://trial.medpath.com/news/02be780e72d91fd7/clarity-pharmaceuticals-secures-large-scale-copper-64-manufacturing-agreement-with-theragenics-for-prostate-cancer-diagnostic 2026-03-25T17:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/7d079f2d21a8d6b9/tropic-biosciences-raises-105-million-series-c-to-scale-gene-edited-tropical-crop-production 2026-03-25T17:05:34+00:00 hourly 0.9 https://trial.medpath.com/news/a42f29ee33504b01/scitech-s-st-001-nanofenretinide-shows-early-clinical-benefit-in-cutaneous-t-cell-lymphoma-phase-1a-trial 2026-03-25T17:05:11+00:00 hourly 0.9 https://trial.medpath.com/news/5d430c334289ae81/axplora-invests-60-million-in-hpapi-manufacturing-expansion-to-meet-growing-adc-demand 2026-03-25T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/b4eb60ba461bccb2/health-canada-approves-apotex-s-clobivis-for-post-cataract-surgery-inflammation-treatment 2026-03-25T17:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/3b5b992688157d52/sirolimus-eluting-balloons-show-promise-as-alternative-to-permanent-stents-in-heart-attack-treatment 2026-03-25T17:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/53cbefb57c978a14/lineage-cell-therapeutics-launches-cor1-cell-therapy-program-to-address-global-corneal-transplant-shortage 2026-03-25T13:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/8aee11c36f6ce4b0/japanese-court-clears-path-for-sawai-s-amitiza-generic-rejecting-viatris-patent-extension-strategy 2026-03-25T13:05:42+00:00 hourly 0.9 https://trial.medpath.com/news/93a3325496e28894/cvc-capital-proposes-eur10-9-billion-takeover-of-italian-pharma-recordati 2026-03-25T13:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/dcef50e43b516b81/verigraft-initiates-pivotal-phase-ii-iii-trial-for-first-potential-curative-cvi-treatment 2026-03-25T13:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/c48049b1cfb7bea4/medtronic-receives-fda-approval-for-expanded-omniasecure-defibrillation-lead-indication 2026-03-25T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/2121de15c7615734/mitsui-chemicals-establishes-drug-discovery-lab-in-kentucky-advancing-next-generation-pharmaceutical-materials 2026-03-25T09:03:50+00:00 hourly 0.9 https://trial.medpath.com/news/43465fc232c7d4ad/veeva-systems-acquires-ai-powered-brand-engagement-platform-ostro-for-100-million 2026-03-25T09:03:39+00:00 hourly 0.9 https://trial.medpath.com/news/67327a6247c9f5b2/hope-medicine-initiates-phase-iii-trial-for-first-in-class-non-hormonal-endometriosis-treatment 2026-03-25T05:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/79303830d57dfce2/absci-s-ai-designed-hair-loss-treatment-abs-201-shows-promising-safety-data-in-phase-1-2a-trial 2026-03-25T01:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/873bfebc02da3237/new-cerebrospinal-fluid-biomarker-achieves-94-97-accuracy-in-diagnosing-parkinson-s-disease-and-lewy-body-dementia 2026-03-25T01:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/6f23a79c0ed8d2a2/biolojic-design-s-ai-designed-multibody-tev-325-achieves-preclinical-milestone-for-autoimmune-disease-treatment 2026-03-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/3b224a5074437e2d/20-20-biolabs-partners-with-rokit-healthcare-to-integrate-ckd-prediction-technology-into-longevity-testing-platform 2026-03-24T21:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/e7634a5271881af4/chinese-researchers-develop-breakthrough-nanoparticle-system-for-scalable-exosome-therapeutic-production 2026-03-24T21:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/7b9c27cae696a889/recce-pharmaceuticals-advances-phase-3-diabetic-foot-infection-trial-following-clean-indonesian-regulatory-inspection 2026-03-24T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/5e23ff1c4d3b1566/boehringer-ingelheim-advances-dll3-targeting-t-cell-engager-obrixtamig-directly-to-phase-3-first-line-small-cell-lung-cancer-trial 2026-03-24T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/c4c5ca82c2506656/myosin-therapeutics-receives-2-million-florida-grant-for-first-in-human-glioblastoma-trial 2026-03-24T21:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/9f58868fa810ff68/remegen-s-disitamab-vedotin-receives-fourth-nmpa-approval-for-her2-low-breast-cancer-in-china 2026-03-24T21:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/aeb91e35920d4058/cytiva-partners-with-san-raffaele-institute-to-advance-hematopoietic-stem-cell-gene-therapies 2026-03-24T21:04:50+00:00 hourly 0.9 https://trial.medpath.com/news/e8d8188b9a3c7c3c/italian-drug-approval-reform-shows-mixed-results-on-negotiation-timelines 2026-03-24T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/07ce887db046a537/fda-issues-warning-letter-to-immunitybio-over-misleading-cancer-drug-claims-by-patrick-soon-shiong 2026-03-24T21:03:49+00:00 hourly 0.9 https://trial.medpath.com/news/3e2728ad29d4dc13/28bio-s-cns-3d-brain-organoids-demonstrate-superior-seizure-prediction-accuracy-over-animal-models 2026-03-24T17:17:16+00:00 hourly 0.9 https://trial.medpath.com/news/c17d612fb02e6758/achieve-life-sciences-partners-with-adare-pharma-for-cytisinicline-manufacturing-ahead-of-fda-decision 2026-03-24T17:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/e3a705d73153c8f5/doctronic-secures-40m-series-b-as-first-ai-system-legally-authorized-to-renew-prescriptions-in-the-u-s 2026-03-24T17:12:13+00:00 hourly 0.9 https://trial.medpath.com/news/0eaf5f31567c6b35/apnimed-secures-150m-from-shionogi-joint-venture-sale-advances-first-in-class-osa-drug-toward-fda-submission 2026-03-24T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/2d99f09d5387a876/major-study-finds-no-link-between-covid-19-vaccines-and-sudden-cardiac-death-in-healthy-young-adults 2026-03-24T17:11:18+00:00 hourly 0.9 https://trial.medpath.com/news/a96968f3758a9dfd/india-launches-world-s-first-clinical-trial-integrating-ayurveda-with-tuberculosis-treatment 2026-03-24T17:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/d2214a622e272919/fda-approved-cancer-drug-doxorubicin-shows-promise-against-drug-resistant-herpes-infections 2026-03-24T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/098a5e55c303a7c8/nice-approves-keytruda-as-first-perioperative-immunotherapy-for-head-and-neck-cancer-in-20-years 2026-03-24T17:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/49b899c15bc2f850/scotland-launches-first-uk-newborn-screening-program-for-spinal-muscular-atrophy 2026-03-24T17:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/3664200a6d923e24/epifrontier-therapeutics-secures-32m-amed-grant-to-advance-first-in-class-g9a-inhibitor-for-beta-globin-disorders 2026-03-24T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/24a570ea07acb558/intensity-therapeutics-secures-new-us-patent-for-intratumoral-cancer-technology 2026-03-24T17:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/9d5437cc271fe266/continuity-biosciences-partners-with-breakthrough-t1d-to-advance-novel-cell-therapy-platform-for-type-1-diabetes 2026-03-24T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/1a381caeef5471dc/medtronic-expands-pain-portfolio-with-fda-cleared-viaverte-basivertebral-nerve-ablation-system 2026-03-24T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/334d2d3bb4e21e2a/mushrooms-inc-achieves-proof-of-concept-for-mycelium-based-infection-detection-technology 2026-03-24T13:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/75e5f63233256f6b/callio-therapeutics-initiates-first-in-human-trial-of-dual-payload-adc-clio-8221-for-her2-positive-solid-tumors 2026-03-24T13:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/5c0d68fe0857221e/dualitybio-achieves-phase-3-success-with-lead-adc-candidate-advances-global-pipeline-across-multiple-cancer-types 2026-03-24T13:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/b9bdc072bf5183c5/immutrin-secures-87-million-series-a-to-advance-novel-antibody-therapy-for-attr-amyloidosis 2026-03-24T13:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/4b378be1a80c5a93/iaso-bio-receives-japan-pmda-approval-for-phase-iii-car-t-trial-in-earlier-line-multiple-myeloma 2026-03-24T13:06:40+00:00 hourly 0.9 https://trial.medpath.com/news/972b030cb16efe9b/prestige-biopharma-s-hd204-biosimilar-meets-primary-endpoint-in-phase-3-nsclc-trial 2026-03-24T13:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/46fb4efd23dd66a4/quotient-therapeutics-partners-with-merck-in-2-2-billion-ibd-drug-discovery-deal-using-somatic-genomics-platform 2026-03-24T13:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/4e982912fc323d36/cortexa-achieves-major-commercial-milestone-with-mdma-supply-in-australia-s-regulated-psychedelic-market 2026-03-24T09:08:18+00:00 hourly 0.9 https://trial.medpath.com/news/13c251b886b14f50/fresenius-challenges-takeda-s-ibd-drug-patents-in-uk-biosimilar-dispute 2026-03-24T09:06:19+00:00 hourly 0.9 https://trial.medpath.com/news/75545c960755186a/kelun-biotech-achieves-breakthrough-in-first-line-nsclc-treatment-with-world-s-first-successful-adc-immunotherapy-combination 2026-03-24T09:05:50+00:00 hourly 0.9 https://trial.medpath.com/news/24c236c6a900dfdc/microbot-medical-launches-full-commercial-release-of-liberty-robotic-system-following-successful-limited-market-adoption 2026-03-24T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/f1621649988b6986/surrozen-advances-wnt-based-retinal-therapeutics-pipeline-plans-ind-filing-for-szn-8141-in-second-half-of-2026 2026-03-24T01:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/9890ab317dad08eb/maat-pharma-s-microbiome-therapy-shows-62-response-rate-in-severe-graft-versus-host-disease 2026-03-24T01:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/ef44b0ce1c79a777/avalyn-initiates-phase-2-trial-of-inhaled-nintedanib-for-idiopathic-pulmonary-fibrosis 2026-03-24T01:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/64fe3028ae0fa404/celosia-therapeutics-initiates-first-in-human-trial-of-ctx1000-gene-therapy-for-als 2026-03-24T01:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/791302385c42c548/cencora-expands-retina-care-network-with-1-1-billion-eyesouth-partners-acquisition 2026-03-24T01:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/2e5281af1bbcf77f/trinity-biotech-s-enhanced-epicapture-test-achieves-85-accuracy-in-prostate-cancer-risk-prediction 2026-03-23T21:08:43+00:00 hourly 0.9 https://trial.medpath.com/news/abdd84db63d7b572/taiwan-approves-pharmamar-s-zepzelca-combination-as-first-line-maintenance-therapy-for-advanced-small-cell-lung-cancer 2026-03-23T21:05:37+00:00 hourly 0.9 https://trial.medpath.com/news/b44a41e059e13033/abpi-proposes-nhs-data-integration-to-revitalize-uk-s-declining-clinical-trial-sector 2026-03-23T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/3f03204d386c909f/quantum-biopharma-s-unbuzzd-supplement-shows-significant-alcohol-metabolism-acceleration-in-peer-reviewed-clinical-trial 2026-03-23T17:15:08+00:00 hourly 0.9 https://trial.medpath.com/news/08e1d1bf84ab35c1/bausch-lomb-s-elios-system-achieves-primary-endpoints-in-24-month-u-s-glaucoma-trial 2026-03-23T17:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/c176473b6e6b7861/sintx-technologies-achieves-first-human-implant-of-fda-cleared-silicon-nitride-foot-and-ankle-device 2026-03-23T17:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/e877e81b0768f692/roche-opens-institute-of-human-biology-in-basel-with-chf-1-4-billion-investment-to-revolutionize-drug-discovery 2026-03-23T17:11:08+00:00 hourly 0.9 https://trial.medpath.com/news/dd97f35cfaf6c68f/viatris-secures-first-ever-gad-treatment-approval-in-japan-with-effexor 2026-03-23T17:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/f224f569ae642f75/german-court-grants-sales-ban-for-generic-fampridine-products-following-patent-victory-for-merz 2026-03-23T17:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/4ab437ae3609ce29/bio-thera-solutions-expands-partnership-with-intas-for-golimumab-biosimilar-bat2506-in-india 2026-03-23T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/ed7c105ecf721b39/fda-grants-priority-review-to-zilganersen-for-alexander-disease-setting-stage-for-first-treatment 2026-03-23T17:09:38+00:00 hourly 0.9 https://trial.medpath.com/news/d68c0e7e927b97d8/godavari-biorefineries-secures-japanese-patent-for-novel-v-atpase-inhibitor-antiviral-compounds 2026-03-23T17:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/7e6f6a5d3f24a024/apollo-acquires-37-stake-in-syntegon-as-pharmaceutical-packaging-giant-eyes-north-american-expansion 2026-03-23T17:08:20+00:00 hourly 0.9 https://trial.medpath.com/news/6f9cca33ba84b263/stealth-biotherapeutics-secures-mrc-grant-to-advance-sbt-589-for-leigh-syndrome-treatment 2026-03-23T17:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/d67eedafdc6bd02e/shionogi-completes-2-5-billion-acquisition-of-radicava-for-als-treatment-expanding-rare-disease-portfolio 2026-03-23T17:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/5e63f5f7b129f59c/enlivex-receives-fda-ind-clearance-for-phase-2b-trial-of-allocetra-in-age-related-knee-osteoarthritis 2026-03-23T17:07:24+00:00 hourly 0.9 https://trial.medpath.com/news/eeba55a54f91ffb0/inmed-s-inm-901-shows-promise-in-human-brain-organoid-models-for-alzheimer-s-disease-treatment 2026-03-23T17:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/071ed0a200363d5f/glyconex-partners-with-nippon-kayaku-to-develop-tumor-activated-adc-gnx201-for-solid-tumors 2026-03-23T17:06:54+00:00 hourly 0.9 https://trial.medpath.com/news/5056f89886311c6e/ondine-s-steriwave-phase-3-trial-reaches-93-enrollment-milestone-in-landmark-surgical-site-infection-prevention-study 2026-03-23T17:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/c67c7bbece207034/biocytogen-partners-with-moonlight-bio-to-develop-advanced-cell-therapies-for-difficult-to-treat-cancers 2026-03-23T17:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/205c87e3adadf4bc/chugai-receives-world-first-approval-for-lunsumio-polivy-combination-in-relapsed-large-b-cell-lymphoma 2026-03-23T13:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/d479cb971487ee62/karmanos-cancer-institute-becomes-first-independent-cancer-center-to-offer-hemophilia-b-gene-therapy 2026-03-23T13:21:34+00:00 hourly 0.9 https://trial.medpath.com/news/9a85829f3efffac6/biolinerx-advances-glix1-glioblastoma-trial-as-company-reports-2025-financial-results 2026-03-23T13:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/9b7fc84f51b8662b/endocyclic-therapeutics-receives-fda-ind-clearance-for-first-in-class-non-hormonal-endometriosis-treatment-endo-205 2026-03-23T13:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/98ab1f3107503bac/laigo-bio-secures-eur17m-in-oversubscribed-seed-round-to-advance-novel-protein-degradation-platform 2026-03-23T13:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/80fc6645f874a6e0/abbott-completes-21-billion-exact-sciences-acquisition-while-novartis-invests-2-billion-in-next-generation-pi3ka-inhibitors 2026-03-23T13:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/e2f19d79c604196a/just-evotec-biologics-secures-10m-barda-contract-to-optimize-filovirus-antibody-manufacturing 2026-03-23T13:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/8183902b3a1a8a78/brain-biotech-secures-european-patent-for-novel-crispr-bmc-genome-editing-technology 2026-03-23T13:16:53+00:00 hourly 0.9 https://trial.medpath.com/news/6dd617603e275fdb/pfizer-and-valneva-s-lyme-disease-vaccine-shows-73-efficacy-in-phase-3-trial 2026-03-23T13:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/099ab90bd96c00d0/fecal-microbiota-transplantation-shows-promise-for-severe-c-difficile-infections-despite-regulatory-challenges 2026-03-23T13:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/3d4a7d5bdd79fe6c/ema-grants-orphan-drug-status-to-uab-s-maresin-1-therapy-for-spinal-cord-injuries 2026-03-23T13:16:40+00:00 hourly 0.9 https://trial.medpath.com/news/96949ef1b630b649/pfizer-valneva-lyme-disease-vaccine-shows-73-efficacy-but-faces-regulatory-hurdle-after-missing-statistical-endpoint 2026-03-23T13:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/1e5b7faddbef1add/indian-courts-strengthen-patent-opposition-framework-in-high-profile-cancer-immunotherapy-and-drug-delivery-cases 2026-03-23T09:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/2edd01266a929542/contezolid-shows-superior-safety-profile-to-linezolid-in-real-world-treatment-of-drug-resistant-infections 2026-03-23T09:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/67d2a8734fd3a285/monash-university-and-clinchoice-form-strategic-partnership-to-accelerate-early-phase-clinical-trials 2026-03-23T09:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/75e03b62d3e65f3a/innovent-biologics-initiates-phase-3-trial-for-novel-gout-drug-tigulixostat-in-china 2026-03-23T05:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/e0cf41cdfc351eb0/harbour-biomed-s-tslp-targeting-antibody-hbm9378-shows-favorable-safety-profile-in-phase-i-trial 2026-03-23T05:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/3f2afc20fa737bbd/pepsico-analyst-targets-fluctuate-as-company-pursues-price-cuts-and-health-focused-product-pipeline-for-2026-turnaround 2026-03-22T21:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/3341ace164907ea6/cdsco-expert-panel-mandates-protocol-revisions-for-glimepiride-linagliptin-combination-phase-iii-trial 2026-03-22T21:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/cbcc9a4c5b7635bc/hepatitis-c-drug-bemnifosbuvir-shows-promise-against-hepatitis-e-virus-in-preclinical-studies 2026-03-22T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/1147974cc169b9c9/vesicor-therapeutics-appoints-michael-tolentino-as-ceo-to-lead-p53-based-cancer-therapy-development 2026-03-22T17:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/b4c9c3d73cb3555a/pfizer-s-comirnaty-vaccine-transitions-to-endemic-phase-with-sustained-european-market-presence 2026-03-22T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/1c76ca85cce06e54/siemens-healthineers-partners-with-imaginostics-to-advance-quantitative-mri-technology-for-magnetom-systems 2026-03-22T13:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/1e033417e7f8fd16/clariant-establishes-first-us-manufacturing-site-for-pharmaceutical-grade-peg-excipients-in-texas 2026-03-22T01:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/1cb7a03e7731a91e/tg-therapeutics-secures-500-million-credit-facility-to-fuel-briumvi-growth-and-pipeline-development 2026-03-21T21:07:17+00:00 hourly 0.9 https://trial.medpath.com/news/985e992ffb701db7/spyre-therapeutics-completes-phase-1-safety-study-of-spy001-001-advancing-early-stage-pipeline 2026-03-21T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/33e70b5eba3727f4/akums-launches-world-s-first-lasmiditan-dispersible-tablets-for-acute-migraine-treatment 2026-03-21T21:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/5b4512370aef8cb0/zegfrovy-achieves-primary-endpoint-in-phase-3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-03-21T17:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/fc6024cd8e0dd0a2/fda-mandates-seizure-risk-warnings-for-parkinson-s-drugs-containing-carbidopa-and-levodopa 2026-03-21T13:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/202acf2599d63ab4/fda-clears-varian-truebeam-systems-for-low-dose-radiation-therapy-in-osteoarthritis 2026-03-21T01:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/e089f26e4856c1c9/incyte-to-present-long-term-povorcitinib-data-for-hidradenitis-suppurativa-at-aad-2026 2026-03-21T01:06:04+00:00 hourly 0.9 https://trial.medpath.com/news/35ae408ca3aa2ade/thermo-fisher-scientific-completes-8-9-billion-clario-acquisition-to-strengthen-clinical-trial-capabilities 2026-03-21T01:05:22+00:00 hourly 0.9 https://trial.medpath.com/news/6163107e04c06f62/smart-hydrogel-wound-dressing-delivers-antibiotics-on-demand-to-combat-resistance 2026-03-20T19:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/b727b879a7359883/leo-pharma-presents-real-world-evidence-for-dermatology-portfolio-at-aad-2026 2026-03-20T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/93d24b37d6d42af5/lab-grown-oesophagus-successfully-restores-swallowing-function-in-pigs-human-trials-planned-within-five-years 2026-03-20T17:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/a8e87962ba659252/biodesix-publishes-largest-lung-nodule-biomarker-validation-study-supporting-earlier-cancer-detection 2026-03-20T17:09:08+00:00 hourly 0.9 https://trial.medpath.com/news/a9a723543bc85a7c/arch-biopartners-advances-lsalt-peptide-phase-ii-trial-for-cardiac-surgery-associated-acute-kidney-injury 2026-03-20T17:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/2a3806d2f3433afd/mixed-results-from-cardiac-resynchronization-trials-challenge-left-bundle-branch-pacing-as-biv-alternative 2026-03-20T15:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/ddfdb4e9e1b8dd55/boehringer-ingelheim-partners-with-emfret-analytics-to-advance-novel-gpvi-inhibitor-ema601-for-stroke-treatment 2026-03-20T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/239ce3c3a42deb17/novartis-acquires-next-generation-pi3ka-inhibitor-snv4818-in-3-billion-deal-to-strengthen-breast-cancer-pipeline 2026-03-20T10:45:28+00:00 hourly 0.9 https://trial.medpath.com/news/b4f89465efc1fcc3/bio-sourcing-and-tiny-cargo-partner-to-develop-first-oral-monoclonal-antibody-platform-using-goat-milk-exosomes 2026-03-20T05:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/39ec0b6a89a1368c/lunai-bioworks-launches-national-chemical-defense-consortium-with-ai-driven-3-year-antidote-development-model 2026-03-20T05:09:11+00:00 hourly 0.9 https://trial.medpath.com/news/3953f5f942a38310/verily-secures-300-million-investment-and-gains-independence-from-alphabet-to-advance-ai-driven-precision-health-platform 2026-03-20T05:09:10+00:00 hourly 0.9 https://trial.medpath.com/news/0cfb6c2054709669/mayo-clinic-pilot-study-demonstrates-safe-home-based-chemotherapy-delivery 2026-03-20T05:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/2ea6d6c5457e1e62/adalta-completes-global-patent-protection-for-anti-fibrotic-drug-ad-214-with-canadian-approval 2026-03-20T05:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/ee0d629c10b08699/nice-ordered-to-reconsider-alzheimer-s-drugs-after-successful-appeals-by-eli-lilly-and-eisai 2026-03-20T05:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/e759a4ab4e8d8740/curis-reports-promising-mrd-conversion-data-for-emavusertib-in-aml-combination-therapy 2026-03-20T01:58:03+00:00 hourly 0.9 https://trial.medpath.com/news/f6b102c36d98e935/collegium-pharmaceutical-acquires-azstarys-for-650-million-to-strengthen-adhd-portfolio 2026-03-19T21:14:32+00:00 hourly 0.9 https://trial.medpath.com/news/003487f47da0c0ca/ac-immune-achieves-first-in-vivo-imaging-of-tdp-43-brain-pathology-with-novel-pet-tracer-aci-19626 2026-03-19T21:12:28+00:00 hourly 0.9 https://trial.medpath.com/news/9ab519a1e5b87324/context-therapeutics-advances-t-cell-engager-pipeline-with-three-bispecific-antibodies-in-clinical-development 2026-03-19T21:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/409766c356445cc4/triana-biomedicines-tri-611-receives-fda-fast-track-designation-for-alk-nsclc-treatment 2026-03-19T21:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/726356879ee0a2ab/experimental-hookworm-vaccine-demonstrates-significant-protection-in-phase-2-human-trial 2026-03-19T21:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/1a12b929d81222d3/glaukos-launches-first-fda-approved-epithelium-on-corneal-cross-linking-treatment-for-keratoconus-in-us 2026-03-19T21:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/03dd9c4484e8b9ba/sarepta-therapeutics-seeks-traditional-approval-for-duchenne-muscular-dystrophy-therapies-following-fda-feedback 2026-03-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/a67941252796b066/convergent-therapeutics-to-present-phase-2-data-for-conv01-a-in-lu-psma-pretreated-metastatic-prostate-cancer-at-asco-2026 2026-03-19T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/7d142b2b0e71a84a/embecta-acquires-owen-mumford-for-ps150-million-to-expand-drug-delivery-platform-capabilities 2026-03-19T17:12:49+00:00 hourly 0.9 https://trial.medpath.com/news/15f9fb12db03532f/altesa-biosciences-vapendavir-shows-first-ever-activity-against-rhinovirus-c-in-breakthrough-research 2026-03-19T17:10:14+00:00 hourly 0.9 https://trial.medpath.com/news/a693e2438af8005d/fda-grants-fast-track-designation-to-remix-therapeutics-rem-422-for-adenoid-cystic-carcinoma-treatment 2026-03-19T17:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/328301cd548d714c/annovis-bio-partners-with-neurorpm-to-deploy-ai-powered-digital-biomarker-technology-in-parkinson-s-disease-clinical-trial 2026-03-19T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/c50af18da9d8fa1f/pfizer-s-talzenna-shows-significant-benefit-in-hormone-sensitive-prostate-cancer-trial 2026-03-19T17:07:55+00:00 hourly 0.9 https://trial.medpath.com/news/50e1801c735052c1/pharmamar-partners-with-globant-to-deploy-ai-powered-drug-discovery-platform-achieving-15x-faster-cancer-research-insights 2026-03-19T17:06:28+00:00 hourly 0.9 https://trial.medpath.com/news/99ad0d4f2ae934d4/providence-medical-technology-launches-superiority-trial-for-corus-lx-lumbar-fusion-system 2026-03-19T17:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/afa55eb322a635c7/cytosorbents-launches-hotswaptm-technology-and-reports-positive-clinical-data-for-blood-purification-therapy 2026-03-19T17:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/3ff67f0fdea19111/livanova-s-aura6000-system-receives-fda-approval-for-obstructive-sleep-apnea-treatment 2026-03-19T17:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/1344fd3f08c04bb2/chemomab-secures-fda-alignment-for-phase-3-trial-of-nebokitug-in-primary-sclerosing-cholangitis 2026-03-19T14:45:48+00:00 hourly 0.9 https://trial.medpath.com/news/915518db36b59569/python-derived-metabolite-shows-promise-as-novel-weight-loss-drug-with-reduced-side-effects 2026-03-19T14:45:36+00:00 hourly 0.9 https://trial.medpath.com/news/ca4972ce07349245/sk-pharmteco-commits-100-million-to-strengthen-viral-vector-manufacturing-capabilities 2026-03-19T14:45:19+00:00 hourly 0.9 https://trial.medpath.com/news/311a0e78e9a0f9cc/lupin-manufacturing-solutions-expands-dabhasa-facility-to-scale-peptide-and-adc-manufacturing-capabilities 2026-03-19T14:44:38+00:00 hourly 0.9 https://trial.medpath.com/news/a9220ab46ca2498b/evotec-and-bristol-myers-squibb-advance-novel-molecular-glue-degrader-bms-986506-into-phase-1-trial-for-kidney-cancer 2026-03-19T14:44:12+00:00 hourly 0.9 https://trial.medpath.com/news/c4b25ca09c6db9dc/belief-biomed-s-gene-therapy-bbm-h901-receives-approval-in-macao-for-hemophilia-b-treatment 2026-03-19T14:44:02+00:00 hourly 0.9 https://trial.medpath.com/news/4fd49fd9cb4bcb63/chugai-files-regulatory-application-for-revolutionary-port-delivery-platform-in-japan 2026-03-19T14:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/0aad6f921ae29834/aspen-neuroscience-s-personalized-parkinson-s-cell-therapy-shows-promise-in-phase-ii-trial-advances-to-pivotal-study 2026-03-19T14:42:00+00:00 hourly 0.9 https://trial.medpath.com/news/ed7a925409d0a945/chinese-scientists-develop-revolutionary-mitochondrial-transplantation-therapy-for-parkinson-s-disease-and-genetic-disorders 2026-03-19T11:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d0a0b755855994b/al-s-pharma-s-ap-101-shows-clinically-meaningful-disease-modification-and-prolonged-survival-in-als-phase-2-trial 2026-03-19T09:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/e4f784d89b98794b/shionogi-initiates-phase-2-trial-for-first-oral-substrate-reduction-therapy-in-late-onset-pompe-disease 2026-03-19T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/3f58583e232c6aab/trisalus-publishes-preclinical-data-showing-enhanced-tumor-delivery-and-immune-activation-with-pedd-delivered-nelitolimod 2026-03-19T05:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/561798ed3cb1bba0/guardant-health-advances-multi-product-growth-strategy-with-quest-partnership-and-fda-milestones 2026-03-19T01:05:29+00:00 hourly 0.9 https://trial.medpath.com/news/f533bf213b7b1549/argentina-repeals-restrictive-pharmaceutical-patent-guidelines-sparking-industry-debate-over-generic-drug-access 2026-03-19T01:04:34+00:00 hourly 0.9 https://trial.medpath.com/news/35c8af36d90fe667/first-michigan-patient-successfully-receives-fda-approved-sickle-cell-gene-therapy-lyfgenia 2026-03-19T01:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/82eacf3ee4860390/louisiana-man-becomes-first-in-southeast-to-receive-gene-therapy-for-sickle-cell-disease 2026-03-19T01:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/a9d7590bc9c90d74/aptamer-group-launches-radiopharmaceutical-program-with-enhanced-stability-profile 2026-03-19T01:03:55+00:00 hourly 0.9 https://trial.medpath.com/news/60e9feb59461e66c/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2026-03-18T21:09:59+00:00 hourly 0.9 https://trial.medpath.com/news/aa19bb4e0bb138da/kupando-raises-eur10-million-to-advance-dual-tlr-agonist-kup101-into-phase-1b-clinical-trial 2026-03-18T21:09:09+00:00 hourly 0.9 https://trial.medpath.com/news/df0ee15b6e04a0a7/artelo-biosciences-enters-16-3-billion-glaucoma-market-with-fully-funded-clinical-trial-of-art27-13 2026-03-18T21:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/84979316f275cb6a/volitionrx-achieves-breakthrough-in-liquid-biopsy-with-99-pure-cancer-dna-isolation 2026-03-18T21:06:43+00:00 hourly 0.9 https://trial.medpath.com/news/759aa19e4e356109/diakonos-oncology-to-present-first-in-class-doc1021-dendritic-cell-therapy-data-at-major-cancer-conferences 2026-03-18T21:05:55+00:00 hourly 0.9 https://trial.medpath.com/news/f4f027046dfe412d/superstring-capital-management-invests-6-84-million-in-cns-drug-developer-axsome-therapeutics 2026-03-18T21:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/07a16f00d9b4bc05/multi-strain-probiotic-shows-promise-in-reducing-bacterial-vaginosis-recurrence 2026-03-18T21:05:38+00:00 hourly 0.9 https://trial.medpath.com/news/6e3a413713946d49/us-appeals-court-revives-false-claims-lawsuit-against-four-pharma-giants-over-340b-drug-pricing-violations 2026-03-18T21:05:33+00:00 hourly 0.9 https://trial.medpath.com/news/b247b66781250b57/mindera-health-and-mountaineer-biosciences-launch-subtilitas-platform-for-precision-dermatology-research 2026-03-18T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/148ad46b9e7fef56/nia-therapeutics-receives-fda-breakthrough-device-designation-for-ai-guided-brain-implant-to-treat-tbi-related-memory-loss 2026-03-18T21:04:43+00:00 hourly 0.9 https://trial.medpath.com/news/451da56aa82a8533/dod-awards-11m-for-novel-ulcerative-colitis-trial-combining-biologic-with-plant-based-nutraceutical 2026-03-18T21:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/c818ad332480b534/new-england-biolabs-and-touchlight-launch-cell-free-dna-synthesis-kit-to-accelerate-gene-therapy-development 2026-03-18T17:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/1b86ad3ea2b013da/crossbow-therapeutics-secures-77-million-series-b-to-advance-tcr-mimetic-cancer-immunotherapies 2026-03-18T17:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/e54011cae88b8f67/jenavalve-s-trilogy-system-becomes-first-fda-approved-tavr-device-for-severe-aortic-regurgitation 2026-03-18T17:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/1503ee9ba61ba483/first-validated-biomarker-transforms-hormone-therapy-decisions-in-recurrent-prostate-cancer 2026-03-18T17:07:18+00:00 hourly 0.9 https://trial.medpath.com/news/28aa6fb2c09fb9e3/atrogi-doses-first-patients-in-phase-1-trial-of-exercise-mimicking-drug-atr-258 2026-03-18T17:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/1e4345989408aa0b/triplet-therapy-doubles-survival-in-her2-positive-breast-cancer-patients-with-leptomeningeal-metastasis 2026-03-18T17:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/f45b99d92ab41e37/trinity-biotech-partners-with-university-at-buffalo-to-develop-novel-sjogren-s-syndrome-biomarkers 2026-03-18T17:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/f526a65a9c6e55bb/excalipoint-therapeutics-secures-68-7-million-in-seed-funding-to-advance-next-generation-t-cell-engager-pipeline 2026-03-18T17:06:57+00:00 hourly 0.9 https://trial.medpath.com/news/7a0bc02332e60108/merit-medical-launches-resilience-tts-esophageal-stent-for-cancer-related-strictures-and-fistulas 2026-03-18T15:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/96fd1a5d097c9f8d/eco-innovation-group-acquires-kepler-gtl-s-patent-portfolio-for-sustainable-aviation-fuel-production 2026-03-18T14:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/76034afe8a019b23/duke-researchers-develop-nasal-swab-test-for-early-alzheimer-s-detection 2026-03-18T13:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/8814c52dae417109/sanofi-commits-180m-for-kali-s-novel-trispecific-antibody-in-autoimmune-disease-partnership 2026-03-18T12:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f4e20a44d9c75dd/vietnam-approves-first-enterovirus-a71-vaccine-as-mvc-and-substipharm-target-southeast-asian-expansion 2026-03-18T09:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/cb79892d26c14dd6/university-of-sheffield-receives-ps1m-grant-to-develop-smart-gel-drug-delivery-system-for-glioblastoma 2026-03-18T05:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/33fd3b8816b0377a/silexion-therapeutics-receives-israeli-regulatory-approval-for-phase-2-3-trial-of-kras-targeting-rnai-therapy-sil204 2026-03-18T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/abf60f0efa3f49b0/akamis-bio-s-ng-350a-shows-50-response-rate-in-locally-advanced-rectal-cancer-phase-1b-trial 2026-03-18T01:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/97e9898343afc496/gsk-ends-flovent-monopoly-after-senate-investigation-reveals-367-million-medicaid-rebate-avoidance 2026-03-18T01:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/e628e33e6fc2e623/zymeworks-advances-novel-ras-targeting-adc-platform-with-clinical-data-from-zw191-at-aacr-2026 2026-03-18T01:07:04+00:00 hourly 0.9 https://trial.medpath.com/news/bab7d8a133c25e5a/immunitas-therapeutics-to-present-first-in-human-data-for-novel-anti-cd161-antibody-imt-009-at-aacr-2026 2026-03-18T01:06:55+00:00 hourly 0.9 https://trial.medpath.com/news/6df7d115d87c8b8f/blossomhill-therapeutics-unveils-next-generation-pan-kras-inhibitors-with-picomolar-potency-at-aacr-2026 2026-03-18T01:06:50+00:00 hourly 0.9 https://trial.medpath.com/news/f6a039a4de44cb72/delhi-high-court-orders-patent-office-to-resolve-novartis-breast-cancer-drug-application-after-13-year-delay 2026-03-18T01:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/e90f7847d9784196/peijia-medical-s-dcwire-micro-guidewire-receives-first-fda-510-k-clearance-opening-u-s-market-entry 2026-03-18T01:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/1e3a27e3a34d58f7/verismo-therapeutics-reports-first-clinical-data-for-novel-multi-chain-kir-car-therapies-at-aacr-2026 2026-03-18T01:05:02+00:00 hourly 0.9 https://trial.medpath.com/news/72ec8b2408d35158/abbott-and-exact-sciences-present-breakthrough-multi-cancer-early-detection-data-at-aacr-2026 2026-03-17T21:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/f4a26d223c50ba50/r1-therapeutics-launches-with-77-5-million-series-a-to-develop-novel-chronic-kidney-disease-treatment 2026-03-17T21:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/6ae8778ab2bd1fef/act-capital-management-invests-8-million-in-tg-therapeutics-despite-30-stock-decline 2026-03-17T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/208480a685e90561/first-european-real-world-analysis-validates-immunowell-jcv-test-for-pml-risk-assessment-in-multiple-sclerosis-patients 2026-03-17T21:06:44+00:00 hourly 0.9 https://trial.medpath.com/news/af4ded2773743968/northwestern-scientists-discover-fructose-metabolism-pathway-drives-glioblastoma-growth-and-immune-suppression 2026-03-17T21:06:07+00:00 hourly 0.9 https://trial.medpath.com/news/b42277ad56e6ff6c/sino-biopharmaceutical-receives-nmpa-approval-for-first-in-class-osteoarthritis-drug-trd221-clinical-trial 2026-03-17T21:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/feb65f3dd2cf218d/egypt-and-takeda-pharmaceutical-strengthen-research-partnership-to-advance-clinical-trials-and-drug-access 2026-03-17T21:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/cced9b017b4287a4/long-term-follow-up-data-confirm-sustained-survival-benefits-of-pd-1-inhibitors-in-nasopharyngeal-and-esophageal-cancers 2026-03-17T21:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/795f99daf462acb3/nice-suspends-resminostat-appraisal-after-company-withdraws-marketing-authorization-application 2026-03-17T21:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/5a3fc6b20cc68bc6/merck-reports-long-term-hpv-vaccine-efficacy-data-spanning-up-to-18-years 2026-03-17T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/d835cb4bfe1cfe78/uc-berkeley-researchers-develop-machine-learning-methods-to-accelerate-drug-development-using-real-world-evidence 2026-03-17T21:03:57+00:00 hourly 0.9 https://trial.medpath.com/news/3cdc5a6bba6943b9/cellprothera-advances-protheracytes-stem-cell-therapy-to-phase-iii-for-post-mi-heart-failure 2026-03-17T21:03:53+00:00 hourly 0.9 https://trial.medpath.com/news/18b8e3efde58ff51/asimov-partners-with-score-pharma-to-develop-enhanced-anti-her2-antibody-therapeutics-for-breast-cancer 2026-03-17T17:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/50c6d8ab85032009/voro-therapeutics-partners-with-daiichi-sankyo-to-develop-tumor-activated-adcs-using-primebody-platform 2026-03-17T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/2bbfc31b115f87d8/grifols-chronos-platform-detects-parkinson-s-disease-biomarkers-up-to-12-years-before-clinical-diagnosis 2026-03-17T17:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/038865edaa3fdcb2/spago-nanomedical-s-177lu-sn201-shows-continued-safety-in-phase-i-iia-trial-across-multiple-solid-tumors 2026-03-17T17:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/2783999d8125bd69/avance-clinical-appoints-liahna-toy-to-lead-global-early-phase-center-of-excellence 2026-03-17T17:10:36+00:00 hourly 0.9 https://trial.medpath.com/news/b8194dbb04854d41/vst-bio-secures-45m-series-a-to-advance-first-in-class-stroke-therapeutic-vb-001-into-human-trials 2026-03-17T17:10:09+00:00 hourly 0.9 https://trial.medpath.com/news/452a8dd48d29130c/taiwan-bio-partners-with-terumo-to-automate-regulatory-t-cell-manufacturing-for-transplant-therapy 2026-03-17T17:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/e1a5f0c2110d3dda/osm-car-t-therapy-shows-promise-against-osteosarcoma-in-preclinical-studies 2026-03-17T17:09:30+00:00 hourly 0.9 https://trial.medpath.com/news/2208dccfa69d8af3/alzpath-s-ptau217-antibody-gains-widespread-validation-at-ad-pd-2026-conference 2026-03-17T17:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/c4192989fe8df0cd/idel-therapeutics-raises-eur9-million-to-advance-direct-cytosolic-drug-delivery-platform-for-cancer-treatment 2026-03-17T17:08:27+00:00 hourly 0.9 https://trial.medpath.com/news/77fe2a86a308356b/liminatus-pharma-plans-phase-1-trial-of-iba101-cd47-blocking-antibody-for-lung-cancer 2026-03-17T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/d23e9108f60fe075/innorna-receives-fda-clearance-for-first-in-class-mrna-therapy-in026-targeting-refractory-gout 2026-03-17T17:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/3ce4df80df8d63c2/start-partners-with-trialing-to-expand-access-to-oncology-clinical-trials-across-europe 2026-03-17T17:04:47+00:00 hourly 0.9 https://trial.medpath.com/news/832009c089c4bced/fda-rejects-aldeyra-s-dry-eye-disease-drug-reproxalap-for-third-time-citing-insufficient-efficacy 2026-03-17T17:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/b1cf7e00ee1c0e2a/researchers-uncover-how-lecanemab-activates-brain-s-immune-cells-to-clear-alzheimer-s-plaques 2026-03-17T17:04:41+00:00 hourly 0.9 https://trial.medpath.com/news/6e1345ba409db971/pixelgen-technologies-partners-with-karolinska-institutet-to-discover-novel-biomarkers-for-cancer-immunotherapy-response 2026-03-17T13:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/27fa463a0629a7e7/landmark-review-finds-no-evidence-of-medicinal-cannabis-efficacy-for-major-mental-health-disorders 2026-03-17T13:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/14b6a9e202d58dc8/immupharma-secures-ps7-5m-funding-to-advance-kapiglucagon-for-type-1-diabetes-artificial-pancreas-systems 2026-03-17T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/80792ea68d57dbfa/crism-therapeutics-secures-fda-orphan-drug-designation-for-brain-cancer-treatment 2026-03-17T13:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/ff56447808ecb1a5/sequential-secures-3-5m-to-develop-ai-powered-platform-for-skin-health-biomarker-discovery 2026-03-17T13:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/8a2604eb52f71fc9/outrun-therapeutics-advances-first-in-class-e6ap-inhibitor-for-hpv-positive-head-and-neck-cancer 2026-03-17T13:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/936ce468b40e24be/merck-presents-positive-phase-3-data-for-oral-pcsk9-inhibitor-enlicitide-at-acc-26 2026-03-17T13:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/526f7743b0bebbd2/r1-therapeutics-launches-with-77-5m-to-develop-novel-kidney-disease-treatment 2026-03-17T13:04:52+00:00 hourly 0.9 https://trial.medpath.com/news/50a9e0e7918a7229/soley-therapeutics-develops-first-in-class-ckap2-modulator-stx-6398-for-cancer-treatment 2026-03-17T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4bc6db45a40ba8d/lightbridge-secures-key-patent-approvals-for-advanced-nuclear-fuel-technology-in-canada-and-europe 2026-03-17T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a48982ab769ad0c2/jamp-pharma-group-launches-generic-enzalutamide-for-prostate-cancer-treatment-in-canada 2026-03-17T05:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/ca2cbd0af8e4c548/scientists-engineer-bacteria-to-transform-plastic-waste-into-parkinson-s-drug-l-dopa 2026-03-17T01:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/e5b4a4e1c8a4eaeb/dual-drug-combinations-show-promise-in-overcoming-multiple-myeloma-resistance 2026-03-17T01:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/f389a7b70449f305/pyc-therapeutics-advances-two-rna-based-therapies-for-inherited-blindness-conditions 2026-03-17T01:06:39+00:00 hourly 0.9 https://trial.medpath.com/news/beb997031bc02bca/novartis-completes-11-billion-bond-sale-to-finance-avidity-biosciences-acquisition 2026-03-17T01:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/f5553356e2644741/ibio-advances-bispecific-antibody-for-pulmonary-hypertension-in-heart-failure-targets-q3-2026-development-candidate 2026-03-17T01:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/2a31bd43076af26b/aptar-s-intranasal-delivery-system-advances-ltr-pharma-s-spontan-phase-ii-trial-for-erectile-dysfunction 2026-03-17T01:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/0c7089ddcf00601b/gnq-insilico-to-go-public-through-500m-spac-deal-advancing-ai-powered-drug-development-platforms 2026-03-17T01:05:24+00:00 hourly 0.9 https://trial.medpath.com/news/ea04f6b25914f4ec/glenmark-announces-us-launch-of-potassium-phosphates-injection-for-hypophosphatemia-treatment 2026-03-17T01:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/c567bf1f24f2b1e4/datatrak-and-tailrd-heart-form-strategic-partnership-to-advance-ai-driven-cardiovascular-clinical-research 2026-03-17T01:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/1712dbefd2d33887/briohealth-reaches-100-briovad-implants-gains-fda-approval-for-pediatric-heart-failure-trial 2026-03-16T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b94fc0ecbcf0a38/solve-gne-advances-first-gene-therapy-for-gne-myopathy-toward-phase-i-clinical-trial 2026-03-16T21:09:33+00:00 hourly 0.9 https://trial.medpath.com/news/9a2a4c69e1b1bbee/avicanna-launches-phase-i-clinical-trial-to-determine-optimal-thc-dosing-for-anxiety-treatment 2026-03-16T21:09:22+00:00 hourly 0.9 https://trial.medpath.com/news/b4666fa79ac61660/sona-nanotech-s-targeted-hyperthermia-therapy-shows-38-tumor-clearance-in-colorectal-cancer-study 2026-03-16T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/ae3c17ba928c7679/sartorius-unveils-eveo-platform-to-transform-cell-therapy-manufacturing-with-90-cost-reduction 2026-03-16T21:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/e6b180523e345e3f/neximmune-advances-nex-ile12-immunotherapy-in-phase-1-trials-with-promising-safety-profile 2026-03-16T21:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/28a331aaebe1e5f6/fda-issues-first-formal-guidance-on-form-483-response-requirements-for-drug-manufacturers 2026-03-16T21:07:20+00:00 hourly 0.9 https://trial.medpath.com/news/89b9a6bb0754fa70/egret-therapeutics-moves-to-acquire-full-ownership-of-first-in-class-pd-1-agonist-for-stroke-related-brain-swelling 2026-03-16T21:06:23+00:00 hourly 0.9 https://trial.medpath.com/news/73c9c51d47194acc/prodeon-medical-s-urocross-expander-system-receives-fda-clearance-for-non-permanent-bph-treatment 2026-03-16T21:05:35+00:00 hourly 0.9 https://trial.medpath.com/news/013640dbe47b8cc7/black-diamond-therapeutics-reports-promising-phase-2-data-for-silevertinib-in-egfr-mutant-cancers 2026-03-16T20:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/55e7db59cce36585/amlogenyx-reports-promising-preclinical-data-for-am805-gene-therapy-in-alzheimer-s-disease-treatment 2026-03-16T17:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/a266b4e01f577699/avethera-gmbh-acquires-fraunhofer-item-braunschweig-site-to-expand-biopharmaceutical-manufacturing 2026-03-16T17:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/3d57d000064d52d0/ternary-therapeutics-secures-ps3-6m-to-advance-ai-driven-molecular-glue-drug-discovery-platform 2026-03-16T17:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/cc295d76a9d002b6/illumina-partners-with-veritas-genetics-to-integrate-whole-genome-sequencing-into-health-insurance-plans 2026-03-16T17:05:12+00:00 hourly 0.9 https://trial.medpath.com/news/45e1a13e216ec563/sentynl-therapeutics-licenses-progerinin-for-hutchinson-gilford-progeria-syndrome-treatment 2026-03-16T17:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/93d421597ecf15d0/elevara-medicines-initiates-phase-2b-trial-of-novel-cdk4-6-inhibitor-elv001-for-treatment-resistant-rheumatoid-arthritis 2026-03-16T17:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/7d77257d97331b9a/lundbeck-reports-positive-phase-1b-results-for-lu-af28996-in-advanced-parkinson-s-disease 2026-03-16T13:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/984d4a44772a5c33/blood-test-shows-96-accuracy-in-detecting-glioblastoma-offering-hope-for-earlier-diagnosis 2026-03-16T13:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/775d16d694ea5323/scinus-group-secures-eur3-million-to-advance-cell-therapy-manufacturing-platform 2026-03-16T13:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/7c366ba504df3225/grit-biotechnologies-receives-fda-ind-clearance-for-gene-edited-til-therapy-gt307 2026-03-16T13:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/c4d1ce8ba46995e5/super-vision-technology-s-i-nys-implant-receives-china-approval-as-world-s-first-treatment-for-congenital-nystagmus 2026-03-16T13:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/07be8233f0a363fd/piramal-pharma-solutions-achieves-major-adc-manufacturing-milestone-with-1500th-batch-delivery 2026-03-16T13:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/87c80002028ce5ad/novel-protein-carrier-boosts-paclitaxel-solubility-3600-fold-in-targeted-cancer-therapy 2026-03-16T09:06:24+00:00 hourly 0.9 https://trial.medpath.com/news/12cad3a84deb0583/gen-pharmaceuticals-receives-ethical-approval-for-phase-ii-parkinson-s-disease-trial-of-mitochondrial-targeting-drug-sul-238 2026-03-16T09:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/379dbeabf55ce107/bayer-s-finerenone-achieves-primary-endpoint-in-phase-iii-find-ckd-trial-for-non-diabetic-chronic-kidney-disease 2026-03-16T09:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/27acdae3f0824ca2/cutia-therapeutics-receives-nmpa-approval-for-topical-dutasteride-clinical-trial-in-androgenetic-alopecia 2026-03-16T05:03:46+00:00 hourly 0.9 https://trial.medpath.com/news/4b739456f8cc9a17/tetratherix-launches-precision-medicine-platform-with-30m-partnership-for-nasal-drug-delivery 2026-03-16T05:03:38+00:00 hourly 0.9 https://trial.medpath.com/news/1e8617aa8b40e953/blinklab-advances-autism-diagnostic-device-toward-fda-clearance-with-pivotal-trial-launch 2026-03-16T05:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/99f9a44d57d8af98/percheron-therapeutics-raises-2-2-million-to-advance-vista-targeting-cancer-therapy-hmbd-002 2026-03-16T01:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/2cf3c1a46bf5edbc/racura-oncology-receives-approval-for-phase-1-trial-of-rc220-combination-therapy-in-egfr-mutant-lung-cancer 2026-03-16T01:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/1a58746e02a420d1/ai-designed-mrna-cancer-vaccine-shows-promise-in-canine-trial-sparks-human-treatment-potential 2026-03-15T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/bc87f94f6aa52505/firefly-neuroscience-discovers-brain-wave-biomarkers-to-distinguish-adhd-subtypes 2026-03-14T21:05:54+00:00 hourly 0.9 https://trial.medpath.com/news/bb7351facb229010/fibrogen-refocuses-on-oncology-pipeline-following-china-divestiture-extends-runway-through-2028 2026-03-14T21:05:19+00:00 hourly 0.9 https://trial.medpath.com/news/85197530f7a1ef15/scientists-engineer-bacteria-to-boost-doxorubicin-production-by-180-overcoming-50-year-manufacturing-challenge 2026-03-14T21:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/037bffaaf65ae85e/uk-patient-becomes-first-to-receive-experimental-antibody-drug-conjugate-for-metastatic-prostate-cancer 2026-03-14T17:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/85e2637774124455/duke-clinical-trial-shows-promising-results-for-first-line-immunotherapy-in-metastatic-colorectal-cancer 2026-03-14T17:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/44e58d6b6f1bcecf/korean-biotech-companies-to-showcase-next-generation-cancer-therapies-at-aacr-2026 2026-03-14T13:03:03+00:00 hourly 0.9 https://trial.medpath.com/news/a12c20fdc3b2ce13/vimgreen-s-a2a-receptor-antagonist-vg081821-receives-first-global-ind-approval-for-nash-treatment 2026-03-14T09:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/29a07a7aa519e204/hawkeye-bio-secures-patent-for-graphene-biosensor-platform-targeting-early-lung-cancer-detection 2026-03-14T09:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/f1a3291f74ece337/duke-engineers-develop-sonopin-technology-to-enhance-delivery-of-large-cancer-therapeutics 2026-03-14T01:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/3dca5bfb39acbda9/fda-advisory-committee-recommends-including-subclade-k-variant-in-fall-2024-flu-vaccines 2026-03-14T01:04:04+00:00 hourly 0.9 https://trial.medpath.com/news/a692e50ed39285c2/eliquis-demonstrates-superior-safety-profile-over-xarelto-in-direct-comparison-trial-for-venous-thrombosis 2026-03-13T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/b200e965ec5728ea/einstein-scientists-develop-novel-car-t-manufacturing-method-to-extend-therapeutic-durability 2026-03-13T21:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/0b70b28f28575665/johnson-johnson-s-erda-idrs-shows-89-complete-response-rate-in-first-in-human-bladder-cancer-study 2026-03-13T21:07:08+00:00 hourly 0.9 https://trial.medpath.com/news/e0630edee4a6df9b/tevogen-bio-s-ai-platform-achieves-breakthrough-in-drug-target-prediction-with-92-accuracy 2026-03-13T21:06:46+00:00 hourly 0.9 https://trial.medpath.com/news/e216bf2a16f433cc/fda-approves-cosentyx-for-pediatric-hidradenitis-suppurativa-marking-first-il-17a-inhibitor-for-adolescents 2026-03-13T21:06:33+00:00 hourly 0.9 https://trial.medpath.com/news/bbb1f44bf0e0a154/lonza-completes-strategic-transformation-with-3-billion-divestment-of-capsules-health-ingredients-business 2026-03-13T21:05:01+00:00 hourly 0.9 https://trial.medpath.com/news/0f4ce07c0ca14602/unixell-biotech-receives-fda-ind-clearance-for-first-ipsc-derived-allogeneic-cell-therapy-for-focal-epilepsy 2026-03-13T17:10:37+00:00 hourly 0.9 https://trial.medpath.com/news/c62936eb575e3265/barinthus-bio-completes-phase-1-celiac-disease-trial-as-company-prepares-for-strategic-merger 2026-03-13T17:10:19+00:00 hourly 0.9 https://trial.medpath.com/news/7693d29e73c5f521/immunitybio-achieves-manufacturing-breakthrough-for-nk-cell-therapy-platform-with-scalable-production-process 2026-03-13T17:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/a3e1e1adc95e6f2b/insulet-recalls-omnipod-5-insulin-pumps-after-18-serious-adverse-events-due-to-internal-tubing-defect 2026-03-13T17:09:16+00:00 hourly 0.9 https://trial.medpath.com/news/1d50fb5cc974be6a/china-approves-desidustat-tablets-for-renal-anemia-addressing-critical-treatment-gap-in-ckd-patients 2026-03-13T17:08:32+00:00 hourly 0.9 https://trial.medpath.com/news/1a7faeef2dd5fa19/aditxt-acquires-ignite-proteomics-for-36-million-to-advance-precision-oncology-platform 2026-03-13T17:07:56+00:00 hourly 0.9 https://trial.medpath.com/news/eece9bbe3932d286/fridge-free-tetanus-and-diphtheria-vaccine-shows-promise-in-phase-1-trials-advances-to-next-clinical-stage 2026-03-13T17:07:47+00:00 hourly 0.9 https://trial.medpath.com/news/69c5d69a7be934d5/china-approves-world-s-first-commercial-brain-computer-interface-for-spinal-cord-injury-treatment 2026-03-13T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/45ed07d092047f7d/who-releases-target-product-profiles-to-guide-development-of-antibiotics-against-priority-pathogens 2026-03-13T17:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/5e12232eaddc0be0/century-health-partners-with-dallas-renal-group-to-advance-ai-driven-research-in-rare-kidney-diseases 2026-03-13T17:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/c5ce9e026129d14a/topical-cream-activates-skin-s-immune-system-to-suppress-cutaneous-squamous-cell-carcinoma-growth 2026-03-13T17:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/07e9d25eecacac4a/major-insurers-expand-coverage-for-peripheral-nerve-stimulation-systems-improving-access-for-chronic-pain-patients 2026-03-13T09:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/2ee3629029104975/creative-biolabs-advances-mrna-therapeutics-with-novel-lnp-conjugation-and-lpp-delivery-platforms 2026-03-13T09:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/23d892086f9101f4/colombia-partners-with-3pbiovian-to-develop-first-domestic-biosimilar-cancer-drug 2026-03-13T09:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/f2fd7670f5098d5a/elicio-therapeutics-reports-encouraging-phase-2-amplify-7p-trial-progress-with-fewer-disease-events-than-projected 2026-03-13T05:04:10+00:00 hourly 0.9 https://trial.medpath.com/news/6f3d44293f908408/eve-health-group-secures-904000-to-advance-reformulated-pharmaceutical-pipeline 2026-03-13T05:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/898a420f58299672/immutep-halts-phase-iii-lung-cancer-trial-after-futility-analysis-shares-plunge-88 2026-03-13T05:03:19+00:00 hourly 0.9 https://trial.medpath.com/news/29e8ff2b694bed1e/immunobrain-reports-phase-1b-results-for-novel-pd-l1-checkpoint-inhibitor-in-alzheimer-s-disease 2026-03-13T02:41:01+00:00 hourly 0.9 https://trial.medpath.com/news/047dc0036fd33800/waiv-raises-33m-to-scale-ai-powered-cancer-precision-testing-platform-globally 2026-03-13T02:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/5e55833d606d1e32/mbx-biosciences-appoints-karen-basbaum-as-chief-business-officer-to-drive-strategic-partnerships 2026-03-12T21:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/2086dc82f70dabc0/costco-partners-with-sesame-and-ivi-rma-to-transform-fertility-care-access-with-80-medication-savings 2026-03-12T21:07:26+00:00 hourly 0.9 https://trial.medpath.com/news/33bf9de6c2096384/amgen-and-sanofi-settle-decade-long-patent-dispute-over-pcsk9-cholesterol-drugs 2026-03-12T21:06:13+00:00 hourly 0.9 https://trial.medpath.com/news/a5314b0817a33517/vienna-s-valanx-biotech-secures-eur3-million-to-advance-precision-adc-platform-for-triple-negative-breast-cancer 2026-03-12T21:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/c18f6b7d14f740e3/biocurie-secures-9-3m-arpa-h-award-to-develop-ai-powered-gene-therapy-manufacturing-platform 2026-03-12T21:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/c65e1b5561ff3135/psiquantum-partners-with-national-cancer-center-japan-to-advance-quantum-computing-in-drug-discovery 2026-03-12T21:04:35+00:00 hourly 0.9 https://trial.medpath.com/news/3d3c50fd2f3ac1a5/structured-exercise-program-reduces-chemo-brain-in-phase-3-trial 2026-03-12T21:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/5b0f2adaa0953405/glp-1-weight-loss-medications-linked-to-nutrient-deficiencies-and-emerging-health-complications 2026-03-12T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/be77a6bb344ddfa4/mestag-therapeutics-to-present-novel-ltbr-agonist-mst-0312-data-at-cancer-immunotherapy-symposium 2026-03-12T17:11:46+00:00 hourly 0.9 https://trial.medpath.com/news/660e01702a3328c3/rice-university-bioengineer-receives-2-2m-gates-foundation-grant-for-revolutionary-long-acting-cell-factory-implants 2026-03-12T17:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/48d6472b603ea01f/nsw-opens-96-million-rna-manufacturing-facility-as-university-of-sydney-spinout-secures-tb-vaccine-funding 2026-03-12T17:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/af853387cd98304f/galimedix-achieves-phase-1-milestone-for-oral-gal-101-in-alzheimer-s-disease-development 2026-03-12T17:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/c9dffe51e9c8542b/aplagon-doses-first-patient-in-phase-2a-trial-of-apac-for-chronic-limb-threatening-ischemia 2026-03-12T17:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/e87271da8caecaf6/ipsen-names-michelle-werner-as-north-america-president-to-drive-growth-strategy 2026-03-12T17:08:25+00:00 hourly 0.9 https://trial.medpath.com/news/47e7c1477832ab8f/natera-launches-zenith-genomics-platform-with-methylation-analysis-for-rare-disease-diagnosis 2026-03-12T17:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/4f361623fc2af8e7/ultragenyx-gene-therapy-dtx301-demonstrates-significant-ammonia-reduction-in-phase-3-otc-deficiency-trial 2026-03-12T17:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/0fc3b8749b727149/medically-supervised-ketogenic-diet-extends-survival-by-34-in-metastatic-pancreatic-cancer-patients 2026-03-12T17:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/de91e8c00ecb09bd/cambridge-scientists-develop-light-driven-method-for-late-stage-drug-modification 2026-03-12T17:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/69a182509809a668/johnson-johnson-receives-fda-approval-for-tecnis-puresee-iol-first-extended-depth-of-focus-lens-without-contrast-sensitivity-warning 2026-03-12T17:06:15+00:00 hourly 0.9 https://trial.medpath.com/news/c3c250f0eaa6522c/soleno-therapeutics-faces-class-action-lawsuit-over-alleged-clinical-trial-integrity-issues-for-prader-willi-syndrome-drug 2026-03-12T17:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/b95d65043b25a21b/cbio-receives-european-clearance-for-first-in-human-trial-of-novel-t-cell-therapy-in-cervical-cancer 2026-03-12T13:07:34+00:00 hourly 0.9 https://trial.medpath.com/news/02a38ed9c55d612d/eli-lilly-warns-of-dangerous-impurity-in-compounded-tirzepatide-b12-combinations 2026-03-12T13:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/982ea229de9991c0/ema-grants-prime-designation-to-tolerogenixx-s-mic-lx-cell-therapy-for-kidney-transplant-tolerance 2026-03-12T13:07:12+00:00 hourly 0.9 https://trial.medpath.com/news/ed669b9513437739/chinese-medical-team-achieves-functional-remission-in-30-type-1-diabetes-patients-through-integrative-medicine-approach 2026-03-12T13:06:11+00:00 hourly 0.9 https://trial.medpath.com/news/15563567c5e99c55/intensity-therapeutics-reports-promising-early-results-for-int230-6-in-triple-negative-breast-cancer-phase-2-trial 2026-03-12T13:05:16+00:00 hourly 0.9 https://trial.medpath.com/news/baf521e50a7b4a13/gsk-partners-with-imperial-and-oxford-to-launch-ps11m-digital-organ-twins-center-for-drug-discovery 2026-03-12T13:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/fcda866fda689919/gesynta-pharma-initiates-phase-ii-trial-of-non-hormonal-endometriosis-treatment-vipoglanstat 2026-03-12T13:03:59+00:00 hourly 0.9 https://trial.medpath.com/news/fd865cbe579532db/genscript-opens-first-european-mrna-production-facility-in-netherlands 2026-03-12T09:03:51+00:00 hourly 0.9 https://trial.medpath.com/news/67b4bcfde316853b/meiji-seika-pharma-launches-phase-i-trial-of-me3241-novel-pd-1-agonist-for-autoimmune-diseases 2026-03-12T09:03:47+00:00 hourly 0.9 https://trial.medpath.com/news/321e2f02a29bbc38/huons-advances-novel-dry-eye-treatment-huc1-394-to-phase-2-clinical-trial 2026-03-12T09:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/7092cebe3b5cb278/eau-guidelines-upgrade-aquablation-therapy-to-strong-surgical-recommendation-for-bph-treatment 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/83b0b4bf038e355c/preludedx-receives-fda-breakthrough-device-designation-for-aidabreast-multi-omic-test-in-early-stage-breast-cancer 2026-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2883a181ca303cc7/connected-drug-delivery-devices-market-set-to-reach-12-7-billion-by-2035-driven-by-chronic-disease-rise-and-digital-health-integration 2026-03-12T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/d63cfde0dbcdccfa/apixaban-shows-superior-safety-profile-over-rivaroxaban-in-major-venous-thromboembolism-trial 2026-03-12T05:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/248e54fd873690e0/mesoblast-appoints-dr-teresa-montagut-to-lead-clinical-development-and-medical-affairs-for-cell-therapy-expansion 2026-03-12T05:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/4361eae40496966b/brazil-launches-world-s-first-pediatric-tafenoquine-treatment-for-malaria-in-indigenous-communities 2026-03-12T05:03:58+00:00 hourly 0.9 https://trial.medpath.com/news/a20a20441b67bb12/pierre-fabre-s-avene-pioneers-ai-enhanced-clinical-studies-for-acne-treatment-in-dermo-cosmetics 2026-03-12T01:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/6fe43f6df4a5760d/proton-beam-therapy-trial-shows-promise-for-mesothelioma-patients-aims-to-double-two-year-survival-rates 2026-03-12T01:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/8433c4db9fe0d45d/romiplostim-prevents-chemotherapy-induced-thrombocytopenia-in-phase-3-trial 2026-03-12T01:04:09+00:00 hourly 0.9